var title_f21_63_22512="Balance walk";
var content_f21_63_22512=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F66423&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F66423&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Balance exercises: Balance walk",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 374px; height: 306px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Good balance helps you walk safely and avoid tripping and falling over objects in your way.",
"    <ol>",
"     <li>",
"      Raise arms to sides, shoulder height.",
"     </li>",
"     <li>",
"      Choose a spot ahead of you and focus on it to keep you steady as you walk.",
"     </li>",
"     <li>",
"      Walk in a straight line with one foot in front of the other.",
"     </li>",
"     <li>",
"      As you walk, lift your back leg. Pause for one second before stepping forward.",
"     </li>",
"     <li>",
"      Repeat for 20 steps, alternating legs.",
"     </li>",
"    </ol>",
"    As you progress, try looking from side to side as you walk, but skip this step if you have inner ear problems.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Go4Life. National Institute on Aging at the National Institutes of Health. Available at: file://go4life.niapublications.org (Accessed December 2, 2011).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_63_22512=[""].join("\n");
var outline_f21_63_22512=null;
var title_f21_63_22513="Hangmans fracture child";
var content_f21_63_22513=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F65350&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F65350&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hangman's fracture child",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 404px; height: 404px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This 3 year old boy with neck pain and a history of osteogenesis imperfecta has bilateral C2 pedicular fractures (white arrow) with minimal kyphosis and anterolisthesis (forward displacement of C2 on C3).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Alison Chantal Caviness, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_63_22513=[""].join("\n");
var outline_f21_63_22513=null;
var title_f21_63_22514="Varicose veins of the thigh and calf";
var content_f21_63_22514=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F56463&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F56463&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Varicose veins of the thigh and calf",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 293px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Varicose veins are subcutaneous dilated veins three millimeters or greater in size. These varicosities involve both saphenous and non-saphenous tributaries of the thigh and calf.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bickley, LS and Szilagyi, P. Bates' Guide to Physical Examination and History Taking, 8th Ed. Philadelphia: Lippincott Williams &amp; Wilkins 2003. Copyright &copy;2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_63_22514=[""].join("\n");
var outline_f21_63_22514=null;
var title_f21_63_22515="Ultrasound of the nuchal cord";
var content_f21_63_22515=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F54917&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F54917&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ultrasound of the nuchal cord",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 364px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Professor Josef Wisser, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_63_22515=[""].join("\n");
var outline_f21_63_22515=null;
var title_f21_63_22516="Ileal pouch construction with enterotomies and linear stapling";
var content_f21_63_22516=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F83915&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F83915&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 521px\">",
"   <div class=\"ttl\">",
"    Ileal pouch construction with enterotomies and linear stapling",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 501px; height: 375px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This picture shows an enterotomy made on the antimesenteric surface of the proximal limb and another near the distal limb of the ileum. A linear stapler is inserted and a pouch constructed between the limbs.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_63_22516=[""].join("\n");
var outline_f21_63_22516=null;
var title_f21_63_22517="Fexofenadine and pseudoephedrine: Patient drug information";
var content_f21_63_22517=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Fexofenadine and pseudoephedrine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/61/5078?source=see_link\">",
"     see \"Fexofenadine and pseudoephedrine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F171136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Allegra-D&reg; 12 Hour;",
"     </li>",
"     <li>",
"      Allegra-D&reg; 24 Hour",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F171137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Allegra-D&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10020833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10020835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease allergy signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691980",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat nose stuffiness.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10020834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702123",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to fexofenadine, pseudoephedrine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703506",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Trouble passing urine, glaucoma, very bad heart disease, or very high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10020839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697161",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an enlarged prostate, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696830",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take antacids with this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10020840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10020842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10020837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696039",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is most useful if started before contact with the allergen. Take at least 1 to 3 hours before.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach. Take 1 hour before or 2 hours after meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694555",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid taking this drug with fruit juice.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10020838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10020843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10020844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12471 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.195.65.247-FCC50AAECF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_63_22517=[""].join("\n");
var outline_f21_63_22517=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171136\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171137\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020833\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020835\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020834\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020839\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020840\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020842\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020837\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020838\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020843\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020844\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/61/5078?source=related_link\">",
"      Fexofenadine and pseudoephedrine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_63_22518="Tonsillectomy post-op";
var content_f21_63_22518=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54064&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54064&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 566px\">",
"   <div class=\"ttl\">",
"    Posterior pharynx after tonsillectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 546px; height: 447px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Post-operative day 6. B) Post-operative day 14. C) Post-operative one year.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD, FAAP, FACS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_63_22518=[""].join("\n");
var outline_f21_63_22518=null;
var title_f21_63_22519="Epoprostenol: Pediatric drug information";
var content_f21_63_22519=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Epoprostenol: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?0/22/359?source=see_link\">",
"    see \"Epoprostenol: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?19/61/20436?source=see_link\">",
"    see \"Epoprostenol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F165855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Flolan&reg;;",
"     </li>",
"     <li>",
"      Veletri&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F165856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Flolan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1011254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Prostaglandin",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F13908498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Doses are expressed in units of",
"     <b>",
"      nanograms",
"     </b>",
"     (ng)/kg/minute.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Pulmonary hypertension:",
"     </b>",
"     Very limited data available; efficacy results variable; optimal dose not established; further studies are needed.",
"     <b>",
"      Note:",
"     </b>",
"     Avoid abrupt withdrawal or sudden large dose reductions when discontinuing therapy to prevent rebound pulmonary hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Continuous I.V. infusion:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Low-dose regimen: Initial: 2 ng/kg/minute slowly titrated to 20 ng/kg/minute over ~3 hours was described in a single case report; epoprostenol was used in a full-term neonate (PNA: 72 hours) for PPHN refractory to inhaled nitric oxide and showed initial improvement in oxygenation index (Golzand, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     High-dose regimen: Initial: 20 ng/kg/minute, slowly titrated (according to oxygenation) at 30-minute intervals over 4-12 hours to a mean dose of 60 ng/kg/minute (range: 30-120 ng/kg/minute) and continued for a mean of 5.3 days (range: 3-10.5 days) was used in an open-label trial of eight neonates (GA: 34-42 weeks; PNA: 3-32 hours) with PPHN (excluding CHD and congenital diaphragmatic hernia) (Eronen, 1997)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1011282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/22/359?source=see_link\">",
"      see \"Epoprostenol: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Doses are expressed in units of",
"     <b>",
"      nanograms",
"     </b>",
"     (ng)/kg/minute.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Pulmonary hypertension:",
"     </b>",
"     Infants, Children, Adolescents, and Adults: Continuous I.V.  infusion:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Initial: 1-2 ng/kg/minute, increase dose in increments of 1-2 ng/kg/minute every 15 minutes or longer until dose-limiting side effects are noted or tolerance limit to epoprostenol is observed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dose adjustment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Increase dose: 1-2 ng/kg/minute increments at intervals of at least 15 minutes if symptoms of pulmonary hypertension persist or recur following improvement. In clinical trials, dosing increases occurred at intervals of 24-48 hours or longer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Decrease dose: 2 ng/kg/minute decrements at intervals of at least 15 minutes in case of dose-limiting pharmacologic (adverse) events. Avoid abrupt withdrawal or sudden large dose reductions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Chronic dosing: The need for increased doses should be expected with chronic use; incremental increases occur more frequently during the first few months after the drug is initiated. The optimal dose in children is not well defined. The mean chronic dose at 1 year of therapy is 20-40 ng/kg/minute in adults, but is 50-80 ng/kg/minute in children (particularly younger children); significant variability in optimal dose occurs in pediatric patients (Barst, 1999; Rosenweig, 1999; Widlitz, 2003).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F165839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 0.5 mg, 1.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Flolan&reg;: 0.5 mg, 1.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Veletri&reg;: 1.5 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F165823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11233737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Orders for epoprostenol are distributed by two sources in the United States. Information on orders or reimbursement assistance may be obtained from either Accredo Health, Inc (1-800-935-6526) or TheraCom, Inc (1-877-356-5264).",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1011285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Continuous I.V. infusion: Administer through a central venous catheter; peripheral infusion may be used temporarily until central line is established. Epoprostenol should be infused in a dedicated lumen exclusive of any other drugs; consider a multilumen catheter if other I.V. medications are routinely administered. Avoid abrupt withdrawal, interruptions in delivery, or sudden large reductions in dosing. Patients should have access to a backup infusion pump and infusion sets. The final concentration of epoprostenol solution is determined by the minimum and maximum flow rates of the infusion pump and desired duration of infusion from the specific reservoir volume. Do not reconstitute or mix with other I.V. fluids or I.V. medications prior to or during administration as epoprostenol is very unstable in neutral or acidic pH solutions. Patients may be discharged using an ambulatory infusion pump.  Appropriate ambulatory infusion  pump should be small and lightweight; be able to adjust infusion rates in 2 ng/kg/minute increments; have occlusion, end of infusion, and low battery alarms; have &plusmn;6% accuracy of the programmed rate; and be positive continuous or pulsatile pressure-driven with intervals &le;3 minutes between pulses. The reservoir should be made of polypropylene, polyvinyl chloride, or glass.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Flolan&reg;:",
"     </b>",
"     Reconstitute with the manufacturer-supplied sterile diluent only (see &ldquo;Preparation of Epoprostenol Infusion&rdquo; table). The final volume (usually 100 mL) is a 24-hour supply and may be divided into 3 equal parts (ie, three 8-hour infusion aliquots); one portion to be administered at present and the two other portions should be stored in the refrigerator until time of administration. During use, a single reservoir of solution may be used at room temperature for a total duration of 8 hours, or used with a cold pouch for administration up to 24 hours (change cold pack every 12 hours).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Veletri&reg;:",
"     </b>",
"     Reconstitute with SWI or NS (see &ldquo;Preparation of Epoprostenol Infusion&rdquo; table).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Immediate dilution:",
"     </b>",
"     Diluted solutions which have been",
"     <b>",
"      immediately",
"     </b>",
"     added to a drug delivery reservoir may be administered immediately or stored at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) for 1-7 days dependent on concentration and time to initiation of therapy (see below).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Immediate use following reconstitution:",
"     </b>",
"     <b>",
"      If administered immediately",
"     </b>",
"     , the following maximum infusion duration at room temperature according to solution concentration is recommended:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     &bull;	&ge;3,000 to &lt;6,000 ng/mL: 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     &bull;	&ge;6,000 to &lt;30,000 ng/mL: 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     &bull;	&ge;30,000 ng/mL: 72 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Stored in a drug delivery reservoir following reconstitution and dilution:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <b>",
"      If stored at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) for 1 day",
"     </b>",
"     , the following maximum infusion duration at room temperature according to the solution concentration is recommended:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     &bull; &lt;6,000 ng/mL: Do not use",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     &bull;	&ge;6,000 to &lt;12,000 ng/mL: 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     &bull;	&ge;12,000 to &lt;30,000 ng/mL: 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     &bull;	&ge;30,000 ng/mL: 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <b>",
"      If stored at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) for &gt;1 to 7 days",
"     </b>",
"     , the following maximum infusion duration at room temperature according to the solution concentration is recommended:",
"    </p>",
"    <p style=\"text-indent:2em;margin-left:6em;\">",
"     &bull; &lt;9,000 ng/mL: Do not use",
"    </p>",
"    <p style=\"text-indent:2em;margin-left:6em;\">",
"     &bull; &ge;9,000 to &lt;30,000 ng/mL: 12 hours",
"    </p>",
"    <p style=\"text-indent:2em;margin-left:6em;\">",
"     &bull; &ge;30,000 ng/mL: 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Delayed dilution: Stored",
"     </b>",
"     [&le;5 days under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F)",
"     <b>",
"      or",
"     </b>",
"     &le;48 hours at room temperature of 25&deg;C (77&deg;F)]",
"     <b>",
"      in the original vial following reconstitution:",
"     </b>",
"     If using",
"     <b>",
"      previously reconstituted and stored",
"     </b>",
"     Veletri&reg; vials, each vial must be further diluted prior to adding to the drug delivery reservoir. Each reservoir diluted to a concentration &ge;15,000 ng/mL can be administered at room temperature for up to 24 hours; if lower concentrations are used, pump reservoirs should be changed every 12 hours.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption>",
"      Preparation of Epoprostenol (Flolan&reg; or Veletri&reg;) Infusion",
"     </caption>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"left\" width=\"200\">",
"     </col>",
"     <col align=\"left\" width=\"200\">",
"     </col>",
"     <thead>",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         To make solution with concentration:",
"        </p>",
"       </th>",
"       <th align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Flolan&reg; Instructions",
"        </p>",
"       </th>",
"       <th align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Veletri&reg; Instructions",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody>",
"      <tr>",
"       <td align=\"center\">",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Note:",
"         </b>",
"         Flolan&reg; may only be prepared with sterile diluent provided.",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Note:",
"         </b>",
"         Veletri&reg; may only be prepared with SWI or NS.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3000 ng/mL",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Reconstitute one 0.5 mg vial with 5 mL supplied diluent to prepare a 100,000 ng/mL solution. Withdraw 3 mL (300,000 ng) and add to 97 mL of supplied diluent to make a total of 100 mL.",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Reconstitute one 1.5 mg vial with 5 mL of SWI or NS to prepare a 300,000 ng/mL solution. Withdraw 1 mL (300,000 ng) and further dilute in 99 mL of the same diluent use to reconstitute to make a total of 100 mL.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5000 ng/mL",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Reconstitute one 0.5 mg vial with 5 mL supplied diluent to prepare a 100,000 ng/mL solution. Withdraw 5 mL (500,000 ng) and add to 95 mL of supplied diluent to make a total of 100 mL.",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         6000 ng/mL",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Reconstitute one 1.5 mg vial with 5 mL of SWI or NS to prepare a 300,000 ng/mL solution. Withdraw 2 mL (600,000 ng/mL) and further dilute in 98 mL of the same diluent used to reconstitute to make a total of 100 mL.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         9000 ng/mL",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Reconstitute one 1.5 mg vial with 5 mL of SWI or NS to prepare a 300,000 ng/mL solution. Withdraw 3 mL (900,000 ng) and further dilute in 97 mL of the same diluent used to reconstitute to make a total of 100 mL.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10,000 ng/mL",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Reconstitute",
"         <span style=\"text-decoration: underline\">",
"          two",
"         </span>",
"         0.5 mg vials each with 5 mL supplied diluent to prepare a 100,000 ng/mL solution per vial. Withdraw 10 mL (1,000,000 ng) and add to 90 mL of supplied diluent to make a total of 100 mL.",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         12,000 ng/mL",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Reconstitute one 1.5 mg vial with 5 mL of SWI or NS to prepare a 300,000 ng/mL solution. Withdraw 4 mL (1,200,000 ng) and further dilute in 96 mL of the same diluent used to reconstitute to make a total of 100 mL.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         15,000 ng/mL",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Reconstitute one 1.5 mg vial with 5 mL supplied diluent to prepare a 300,000 ng/mL solution. Withdraw 5 mL (1,500,000 ng) and add to 95 mL of supplied diluent to make a total of 100 mL.",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Reconstitute one 1.5 mg vial with 5 mL of SWI or NS to prepare a 300,000 ng/mL solution. Withdraw 5 mL (1,500,000 ng) and further dilute in 95 mL of the same diluent used to reconstitute to make a total of 100 mL.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         20,000 ng/mL",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Reconstitute",
"         <span style=\"text-decoration: underline\">",
"          two",
"         </span>",
"         0.5 mg vials each with 5 mL supplied diluent to prepare a 100,000 ng/mL solution per vial. Withdraw 10 mL (1,000,000 ng) and add to 40 mL of supplied diluent to make a total of",
"         <b>",
"          50 mL",
"         </b>",
"         (DeWet, 2004).",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         30,000 ng/mL",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Reconstitute",
"         <span style=\"text-decoration: underline\">",
"          two",
"         </span>",
"         1.5 mg vials each with 5 mL of SWI or NS to prepare a 300,000 ng/mL solution. Withdraw 10 mL (3,000,000 ng) and further dilute in 90 mL of the same diluent used to reconstitute to make a total of 100 mL.",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F1011275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Compatible",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, and NS solutions. Do not mix or administer with any other drugs prior to or during administration. Stable for 8 hours at room temperature.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1011271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Flolan&reg;:",
"     </b>",
"     Store unopened vials of drug and sterile diluent at room temperature of 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F); protect drug vials from light; do not freeze diluent. Following reconstitution, solution must be stored under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) if not used immediately; reconstituted solution is stable for up to 48 hours when refrigerated; protect from light; do not freeze (discard if solution has been frozen). Total storage and infusion time must not exceed 48 hours for reconstituted solutions. Reconstituted solution (pH 10.2-10.8) is increasingly unstable at a lower pH and drug is rapidly hydrolyzed at the pH of I.V. fluids.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Following dilution, each reservoir of solution may be refrigerated for &le;40 hours and infused at room temperature not to exceed 25&deg;C (77&deg;F) for &le;8 hours; alternatively, each reservoir may be refrigerated for &le;24 hours and infused with the use of a cold pouch for &le;24 hours. Cold pouch should be changed every 12 hours and must be capable of maintaining the reconstituted solution at a temperature between 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) for 12 hours. Protect diluted solution from light.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Veletri&reg;:",
"     </b>",
"     Store unopened vials at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); do not freeze (discard if solution has been frozen). Protect from light. Following reconstitution, solution may be stored under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) up to 5 days or at room temperature of 25&deg;C (77&deg;F) up to 48 hours if not used immediately; do not freeze (discard if solution has been frozen). Protect from light. Discard if refrigerated for &gt;5 days or if at room temperature for &gt;48 hours. Discard unused portion of vial (vial is for single use only).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Following dilution, solutions which have been",
"     <b>",
"      immediately",
"     </b>",
"     added to a drug delivery reservoir may be administered immediately or stored at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) for 1-7 days (dependent on concentration and time to initiation of infusion).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1011255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Treatment of pulmonary arterial hypertension (PAH) (WHO Group I) to improve exercise capacity.",
"     <b>",
"      Note:",
"     </b>",
"     Efficacy has been established in patients with NYHA Class III or IV symptoms with idiopathic or heritable PAH or PAH associated with connective tissue diseases (FDA approved in adults)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Has also been used diagnostically as a short-term I.V. infusion in patients with pulmonary hypertension in the cardiac catheterization laboratory to screen for responsiveness to other oral vasodilating agents (eg, calcium channel blockers).",
"     <b>",
"      Note:",
"     </b>",
"     Responsiveness to short-term (acute) I.V. infusions of epoprostenol predicts responsiveness to long-term treatment with oral calcium channel blockers; however, it does not predict responsiveness to long-term I.V. epoprostenol therapy. Patients who do not respond acutely to epoprostenol may respond to the drug when used chronically.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Other potential uses include treatment of secondary pulmonary hypertension associated with ARDS, SLE, congenital heart disease, congenital diaphragmatic hernia, neonatal pulmonary hypertension, cardiopulmonary bypass surgery, hemodialysis, peripheral vascular disorders, portal hypertension, and neonatal purpura fulminans.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5174529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F165884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Adverse events reported during dose initiation and escalation include flushing, headache, nausea/vomiting, hypotension, anxiety/nervousness/agitation, chest pain; dizziness, abdominal pain, bradycardia, musculoskeletal pain, dyspnea, back pain, diaphoresis, dyspepsia, hypoesthesia/paresthesia, and tachycardia are also reported. Although some adverse reactions may be related to the underlying disease state, abdominal pain, anxiety/nervousness/agitation, arthralgia, bleeding, bradycardia, diarrhea, diaphoresis, flu-like syndrome, flushing, headache, hypotension, jaw pain, nausea, pain, pulmonary edema, rash, tachycardia, thrombocytopenia, and vomiting are clearly contributed to epoprostenol. The following adverse events have been reported during chronic administration for idiopathic or heritable PAH:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Cardiovascular: Flushing, hypotension, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Anxiety, chills, dizziness, fever, flu-like syndrome, nervousness, sepsis, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Dermatologic:  Eczema, rash, skin ulcer, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Local: Injection site reactions: Infection, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, arthritis, hyper-/hypoesthesia, jaw pain, musculoskeletal pain, myalgia, neck pain, pain, paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Anemia, fatigue, hepatic failure, hypersplenism, hyperthyroidism, pallor, pancytopenia, pulmonary embolism, splenomegaly, thrombocytopenia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1011259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to epoprostenol, any component, or structurally-related compounds; chronic use in patients with CHF due to severe left ventricular systolic dysfunction.",
"     <b>",
"      Note:",
"     </b>",
"     Do not use epoprostenol chronically in patients who develop pulmonary edema during dose initiation.",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F2888439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Use with caution and appropriately monitor patients; epoprostenol is a potent pulmonary and systemic vasodilator; it should be used only by clinicians who are experienced in the diagnosis and treatment of pulmonary hypertension; dose initiation must occur in a setting with adequately trained personnel and proper equipment for physiologic monitoring and emergency care. Asymptomatic increases in pulmonary artery pressure, associated with increases in cardiac output, may rarely occur during dose initiation; consider dosage reduction in these patients. During chronic use, unless contraindicated, anticoagulants should be coadministered in adult patients to reduce the risk of thromboembolism [",
"     <b>",
"      Note:",
"     </b>",
"     The use of anticoagulants in",
"     <b>",
"      adult",
"     </b>",
"     patients with primary pulmonary hypertension has been shown to improve survival. Although such efficacy has",
"     <b>",
"      not",
"     </b>",
"     been demonstrated in pediatric patients, some studies have reported the routine use of warfarin in pediatric patients receiving long-term (chronic) infusions of epoprostenol for pulmonary hypertension (Barst, 1999; Rosenzweig, 1999), while other studies have routinely discontinued anticoagulants prior to the initiation of epoprostenol therapy (Higenbottam, 1993). Epoprostenol is a potent inhibitor of platelet aggregation; monitor patients for bleeding, especially those with other risk factors or medications which may increase the risk for hemorrhage. Further studies are needed to assess the risks and benefits of routine anticoagulation in pediatric patients treated with epoprostenol.]",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1011260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Epoprostenol",
"     <b>",
"      must",
"     </b>",
"     only be reconstituted with a product-specific diluent (Flolan&reg;: manufacturer-supplied diluent; Veletri&reg;: SWI or NS); do",
"     <b>",
"      not",
"     </b>",
"     reconstitute or mix with other I.V. fluids or I.V. medications prior to or during administration. Abrupt withdrawal, interruptions in drug delivery, or sudden reductions in epoprostenol dosage may result in symptoms associated with rebound pulmonary hypertension (eg, asthenia, dizziness, dyspnea) and can be potentially fatal; avoid abrupt withdrawal, interruptions in drug delivery, and sudden large reductions in dosage. Immediate access to back up infusion pump and I.V. infusion sets is essential to prevent treatment interruptions. Pulmonary edema, which may be associated with pulmonary veno-occlusive disease may develop in patients with pulmonary hypertension during epoprostenol dose initiation (do not use epoprostenol chronically in these patients).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Symptoms of overdose include headache, hypotension, tachycardia, nausea, vomiting, diarrhea, and flushing. Reduce the infusion rate to decrease symptoms. If symptoms do not subside or worsen, consider drug discontinuation. Fatalities due to hypoxemia, hypotension, and respiratory arrest have been reported following overdose with epoprostenol.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F165832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Prostacyclin Analogues may enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Prostacyclin Analogues may enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: Prostacyclin Analogues may enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F165834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2521390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not reported in animal studies. There are no adequate and well-controlled studies in pregnant women. Women with IPAH are encouraged to avoid pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1011287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hemodynamic effects (pulmonary vascular resistance, pulmonary arterial pressure, systemic blood pressure, heart rate). Monitor blood pressure (standing and supine) and heart rate closely for several hours following dosage adjustments. Monitor for improvements in exercise capacity, exertional dyspnea, fatigue, syncope, chest pain, and quality of life. Monitor the infusion pump device and catheters to avoid drug delivery system related failures. Monitor weight; serum potassium.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1011276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Epoprostenol (also known as prostacyclin, PGI",
"     <sub>",
"      2",
"     </sub>",
"     and PGX), is a metabolite of arachidonic acid and a naturally-occurring prostaglandin. It is a potent, direct-acting, vasodilator of pulmonary and systemic arterial vascular beds. In addition, it inhibits platelet aggregation and vascular smooth muscle proliferation. The reduction in platelet aggregation results from epoprostenol's activation of intracellular adenylate cyclase and the resultant increase in cyclic adenosine monophosphate concentrations within the platelets;",
"     <b>",
"      Note:",
"     </b>",
"     Patients with PPH have an imbalance in the ratio of thromboxane to prostacyclin metabolites and have a decreased amount of prostacyclin synthase in the pulmonary arteries.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Clinically, the vasodilator effects decrease right ventricular and left ventricular afterload and increase cardiac output and stroke volume. Epoprostenol decreases pulmonary vascular resistance, mean pulmonary artery pressure, and mean systemic arterial pressure. Additionally, it is capable of decreasing thrombogenesis and platelet clumping in the lungs by inhibiting platelet aggregation. Studies have demonstrated an increase in exercise capacity and improvements in dyspnea and fatigue.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1011278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Rapidly hydrolyzed at a neutral pH in blood; also metabolized by enzymatic degradation; two primary metabolites with pharmacologic activity less than epoprostenol are formed: 6-keto-PGF",
"     <sub>",
"      1alpha",
"     </sub>",
"     (via spontaneous degradation) and 6,15-diketo-13,14-dihydro-PGF",
"     <sub>",
"      1alpha",
"     </sub>",
"     (via enzymatic degradation); 14 minor metabolites have also been isolated in the urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: &le;6 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (84% of dose); feces (4%)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1011290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?19/61/20436?source=see_link\">",
"      see \"Epoprostenol: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For most adult patients and some pediatric patients, therapy with this medication will probably be prolonged, possibly for years. This medication is infused through a permanent indwelling central venous catheter, on a continuous basis, by a small, portable infusion pump. Interruptions of the infusion (even for a brief time) may result in a rapid symptomatic deterioration of the patient. The patient or caregiver must become familiar with and perform a sterile technique to prepare and administer the medication and to care for the central venous catheter.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     This medication may cause jaw pain, headache, diarrhea, nervousness, and muscular pains (use of a mild analgesia may be recommended by your prescriber); may cause dizziness and impair ability to perform activities requiring mental alertness or physical coordination. Report immediately any signs or symptoms of acute or severe headache; back pain; increased difficult breathing; flushing; fever or chills; any unusual bleeding or bruising; chest pain; palpitations; irregular, slow or fast pulse; flushing; loss of sensation; or any onset of unresolved diarrhea.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F2888581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     The primary role of epoprostenol is in the treatment of primary pulmonary hypertension in patients unresponsive to other therapy. Response to initial therapy is evaluated in a controlled setting before chronic therapy is administered. The role of epoprostenol in the treatment of heart failure confers a negative impact on cardiovascular morbidity and mortality. Clinical trials in adults showed improvement of heart failure symptoms and exercise tolerance, but an increase in mortality.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Barst RJ, \"Pharmacologically Induced Pulmonary Vasodilatation in Children and Young Adults With Primary Pulmonary Hypertension,\"",
"      <i>",
"       Chest",
"      </i>",
"      , 1986, 89(4):497-503.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/63/22519/abstract-text/2869919/pubmed\" id=\"2869919\" target=\"_blank\">",
"        2869919",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barst RJ, Maislin G, and Fishman AP, \"Vasodilator Therapy for Primary Pulmonary Hypertension in Children,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 1999, 99(9):1197-208.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/63/22519/abstract-text/10069788 /pubmed\" id=\"10069788 \" target=\"_blank\">",
"        10069788",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barst RJ, Rubin LJ, Long WA, et al, \"A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) With Conventional Therapy for Primary Pulmonary Hypertension. The Primary Pulmonary Hypertension Study Group,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1996, 334(5):296-302.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/63/22519/abstract-text/8532025/pubmed\" id=\"8532025\" target=\"_blank\">",
"        8532025",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      De Wet CJ, Affleck DG, Jacobsohn E, et al, \"Inhaled Prostacyclin Is Safe, Effective, and Affordable in Patients With Pulmonary Hypertension, Right Heart Dysfunction, and Refractory Hypoxemia After Cardiothoracic Surgery,\"",
"      <i>",
"       J Thorac Cardiovasc Surg",
"      </i>",
"      , 2004, 127(4):1058-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/63/22519/abstract-text/15052203/pubmed\" id=\"15052203\" target=\"_blank\">",
"        15052203",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eronen M, Pohjavuori M, Andersson S, et al, \"Prostacyclin Treatment for Persistent Pulmonary Hypertension of the Newborn,\"",
"      <i>",
"       Pediatr Cardiol",
"      </i>",
"      , 1997, 18(1):3-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/63/22519/abstract-text/8960484/pubmed\" id=\"8960484\" target=\"_blank\">",
"        8960484",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Golzand E, Bar-Oz B, and Arad I, \"Intravenous Prostacyclin in the Treatment of Persistent Pulmonary Hypertension of the Newborn Refractory to Inhaled Nitric Oxide,\"",
"      <i>",
"       Isr Med Assoc J",
"      </i>",
"      , 2005, 7(6):408-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/63/22519/abstract-text/15984391/pubmed\" id=\"15984391\" target=\"_blank\">",
"        15984391",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Higenbottam TW, Spiegelhalter D, Scott JP, et al, &ldquo;Prostacyclin (Epoprostenol) and Heart-Lung Transplantation as Treatments for Severe Pulmonary Hypertension,&rdquo; Br Heart J, 1994, 70:366-70.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kermode J, Butt W, and Shann F, \"Comparison Between Prostaglandin E1 and Epoprostenol (Prostacyclin) in Infants After Heart Surgery,\"",
"      <i>",
"       Br Heart J",
"      </i>",
"      , 1991, 66(2):175-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/63/22519/abstract-text/1883670/pubmed\" id=\"1883670\" target=\"_blank\">",
"        1883670",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rosenzweig EB, Kerstein D, and Barst RJ, \"Long-Term Prostacyclin for Pulmonary Hypertension With Associated Congenital Heart Defects,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 1999, 99(14):1858-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/63/22519/abstract-text/10199883 /pubmed\" id=\"10199883 \" target=\"_blank\">",
"        10199883",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Widlitz A and Barst RJ, \"Pulmonary Arterial Hypertension in Children,\"",
"      <i>",
"       Eur Respir J",
"      </i>",
"      , 2003, 21(1):155-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/63/22519/abstract-text/12570125/pubmed\" id=\"12570125\" target=\"_blank\">",
"        12570125",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13139 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-125.39.66.146-C1CFDD43C6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_63_22519=[""].join("\n");
var outline_f21_63_22519=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165855\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165856\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1011254\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13908498\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1011282\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165839\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165823\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11233737\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1011285\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1011275\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1011271\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1011255\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5174529\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165884\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1011259\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2888439\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1011260\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299275\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165832\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165834\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2521390\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1011287\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1011276\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1011278\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1011290\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2888581\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13139\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13139|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/22/359?source=related_link\">",
"      Epoprostenol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?19/61/20436?source=related_link\">",
"      Epoprostenol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_63_22520="Disorders of ventilatory control";
var content_f21_63_22520=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Disorders of ventilatory control",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/63/22520/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/63/22520/contributors\">",
"     Douglas C Johnson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/63/22520/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/63/22520/contributors\">",
"     Ruth Benca, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/63/22520/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/63/22520/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/63/22520/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The respiratory system is dependent upon a complex system of ventilatory control to ensure appropriate and adequate ventilation in order to supply oxygen, remove carbon dioxide, and maintain acid-base homeostasis. Respiratory centers in the brain integrate input from neural and chemical receptors and provide neuronal drive to the respiratory muscles, which maintain upper airway patency and drive the thoracic bellows to determine the level of ventilation.",
"   </p>",
"   <p>",
"    The abnormalities of ventilatory control that result from a variety of disorders, including chronic obstructive pulmonary disease, asthma, Ondine's curse, carotid body resection, Cheyne-Stokes respiration, myxedema, starvation, and neuromuscular disease, will be reviewed here. In addition, the effects of several pharmacologic agents on ventilation and ventilatory control will be reviewed. The physiologic aspects of ventilatory control and the evaluation of patients with disorders of ventilation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40008?source=see_link\">",
"     \"Control of ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CHRONIC OBSTRUCTIVE PULMONARY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Development of hypercapnia is inconsistent among patients with chronic obstructive pulmonary disease (COPD) and similar degrees of airflow obstruction. COPD patients exhibiting the \"blue bloater\" profile of hypercapnia (CO",
"    <sub>",
"     2",
"    </sub>",
"    retention, ie, elevated PaCO",
"    <sub>",
"     2",
"    </sub>",
"    ) and hypoxemia have decreased respiratory drive compared with \"pink puffers,\" who are eucapnic and have relatively normal oxygen levels [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22520/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pattern of breathing in patients with chronic CO",
"    <sub>",
"     2",
"    </sub>",
"    retention is characterized by a low tidal volume and high frequency, usually &ge;22",
"    <span class=\"nowrap\">",
"     breaths/minute.",
"    </span>",
"    This respiratory pattern in combination with impaired matching of ventilation and perfusion leads to increased dead space ventilation and diminished alveolar ventilation, which contributes to CO",
"    <sub>",
"     2",
"    </sub>",
"    retention [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22520/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some hypercapnic, hypoxemic patients with COPD develop increased CO",
"    <sub>",
"     2",
"    </sub>",
"    retention when O",
"    <sub>",
"     2",
"    </sub>",
"    is administered. Such patients usually have both blunted hypercapnic and hypoxic drives [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22520/abstract/4\">",
"     4",
"    </a>",
"    ]. Other factors contributing to CO",
"    <sub>",
"     2",
"    </sub>",
"    retention during O",
"    <sub>",
"     2",
"    </sub>",
"    breathing include worsening of ventilation-perfusion distribution secondary to relief of compensatory pulmonary vasoconstriction [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22520/abstract/5\">",
"     5",
"    </a>",
"    ], and unloading of CO",
"    <sub>",
"     2",
"    </sub>",
"    due to the Haldane effect [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22520/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/63/3064?source=see_link\">",
"     \"Use of oxygen in patients with hypercapnia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ASTHMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some patients with asthma, an increased risk of near fatal asthma exacerbations, characterized by severe hypoxemia and hypercapnia, is associated with a depressed ventilatory drive. Even during periods of disease quiescence when patients have no bronchospasm, patients with a history of near fatal asthma demonstrate depressed hypoxic and hypercapnic ventilatory responses as well as a reduced perception of dyspnea with added resistive loads (",
"    <a class=\"graphic graphic_figure graphicRef61737 \" href=\"UTD.htm?42/0/43022\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef62712 \" href=\"UTD.htm?5/21/5470\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22520/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/26/13735?source=see_link\">",
"     \"Identifying patients at risk for fatal asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with asthma who have depressed chemosensitivity and inappropriately low sensations of dyspnea probably delay seeking medical treatment during an asthma attack, resulting in their increased risk of fatal asthma. Asthmatic subjects who develop CO",
"    <sub>",
"     2",
"    </sub>",
"    retention during an asthma attack are likely to repeat the same in subsequent attacks [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22520/abstract/7-9\">",
"     7-9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ONDINE'S CURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term Ondine's curse has been applied to patients with alveolar hypoventilation due to impaired autonomic control of ventilation, but whose voluntary control remains intact. Classically, they \"forget to breathe\" when they fall asleep, but maintain relatively normal blood gases while awake [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22520/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ondine's curse is usually due to congenital central hypoventilation syndrome (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Congenital central hypoventilation syndrome'",
"    </a>",
"    below), but can also be caused by brainstem tumors and surgical incisions into the second cervical segment of the spinal cord to relieve intractable pain [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22520/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Paroxysmal central apnea has also been observed following medullary infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22520/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10087?source=see_link&amp;anchor=H15#H15\">",
"     \"Stroke-related pulmonary complications and abnormal respiratory patterns\", section on 'Apnea'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Congenital central hypoventilation syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital central hypoventilation syndrome (CCHS) is associated with a nearly absent respiratory response to hypoxia and hypercapnia, no respiratory discomfort during CO",
"    <sub>",
"     2",
"    </sub>",
"    inhalation, mildly elevated arterial carbon dioxide tension (PaCO",
"    <sub>",
"     2",
"    </sub>",
"    ) during wakefulness, and markedly elevated PaCO",
"    <sub>",
"     2",
"    </sub>",
"    during non-REM sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22520/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. Patients with CCHS increase their ventilation and maintain relatively normal PaCO",
"    <sub>",
"     2",
"    </sub>",
"    levels during exercise, and lower their PaCO",
"    <sub>",
"     2",
"    </sub>",
"    during passive leg cycling due to nonchemoreceptive inputs [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22520/abstract/20-23\">",
"     20-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CCHS can occur in association with Hirschsprung's disease, a condition characterized by abnormalities of the cholinergic innervation of the gastrointestinal tract [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22520/abstract/24\">",
"     24",
"    </a>",
"    ]. The estimated incidence of Hirschsprung's disease among patients with CCHS (also called Ondine-Hirschsprung syndrome or Haddad syndrome) ranges from 10 to 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22520/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Patients with CCHS are also at increased risk of neuroblastoma and ganglioneuroma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22520/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41848?source=see_link\">",
"     \"Congenital aganglionic megacolon (Hirschsprung disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These associations, and the demonstration of subtle autonomic abnormalities in relatives of patients with CCHS, suggest that autonomic neuropathy, particularly of the parasympathetic system, is pathophysiologically important in CCHS [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22520/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. Abnormalities of the gene encoding the transcription factor PHOX2b, which is active during neuronal development, have been implicated in the pathogenesis of CCHS [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22520/abstract/24,29-37\">",
"     24,29-37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Therapy for CCHS may include ventilatory support [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22520/abstract/36\">",
"     36",
"    </a>",
"    ]. In one study, up to 50 percent of all patients surviving longer than one year after birth required nocturnal ventilatory support [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22520/abstract/24\">",
"     24",
"    </a>",
"    ]. One intriguing study noted that passive motion of the lower extremities increased alveolar ventilation and decreased hypercarbia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22520/abstract/23\">",
"     23",
"    </a>",
"    ]. Six patients with CCHS who required chronic nocturnal ventilator support were studied during 74 separate episodes of NREM sleep. Manual or mechanically-assisted passive lower extremity motion was compared to holding the feet without motion. End-tidal PCO",
"    <sub>",
"     2",
"    </sub>",
"    decreased in association with passive lower extremity motion (from 59 to 41 mmHg [7.85 to 5.45 kPa]), with an associated increase in respiratory rate from 10 to 21 breaths per minute. These parameters were unchanged during trials in which the patient's lower extremities were stationary. The mechanism of this effect is unclear, but may relate to activation of peripheral mechanoreceptors or entrainment of the respiratory musculature by lower extremity activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Late-onset central hypoventilation syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike congenital central hypoventilation syndrome, which has neonatal onset, late-onset central hypoventilation syndrome (CHS) can develop anytime from infancy through adulthood. In a study of 25 patients with late-onset CHS, heterozygous PHOX2B mutations were found in 17 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22520/abstract/38\">",
"     38",
"    </a>",
"    ]. This mutation shows incomplete penetrance and variable degrees of phenotypic expression [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22520/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CAROTID BODY RESECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carotid body resection, or glomectomy, was introduced as a treatment for asthma in Japan during the 1940s, and used in the United States until the 1960s, when controlled studies of the procedure did not support its efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22520/abstract/39\">",
"     39",
"    </a>",
"    ]. Glomectomy depresses the hypoxic ventilatory response during exercise; minor abnormalities may also be seen in CO",
"    <sub>",
"     2",
"    </sub>",
"    regulation during exercise, but eucapnia is generally present at rest [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22520/abstract/40\">",
"     40",
"    </a>",
"    ]. Bilateral endarterectomy for carotid occlusive disease also may result in destruction of peripheral chemoreceptors, with diminution of hypoxic ventilatory response and slight elevation of resting PaCO",
"    <sub>",
"     2",
"    </sub>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CHEYNE-STOKES RESPIRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cheyne-Stokes respiration (CSR) describes cyclic breathing in which apnea is followed by gradually increasing respiratory frequency and tidal volume (ie, hyperpnea), then gradually decreasing respiratory frequency and tidal volume until the next apneic period [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22520/abstract/41\">",
"     41",
"    </a>",
"    ]. It is considered a type of central sleep apnea syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15286?source=see_link&amp;anchor=H22#H22\">",
"     \"Sleep related breathing disorders in adults: Definitions\", section on 'Cheyne-Stokes breathing pattern'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/43/8888?source=see_link\">",
"     \"Cheyne-Stokes breathing and obstructive sleep apnea in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Mechanism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delay between changes in ventilation and detection of the resulting arterial tension of carbon dioxide (ie, PaCO",
"    <sub>",
"     2",
"    </sub>",
"    ) by the central chemoreceptors maintains a cyclic pattern of respiration. Factors contributing to this delay include prolonged lung to brain circulation time, reduced tissue and lung CO",
"    <sub>",
"     2",
"    </sub>",
"    and O",
"    <sub>",
"     2",
"    </sub>",
"    stores, and increased ventilatory drive. The increased ventilatory drive is due, at least in part, to loss of effective damping factors.",
"   </p>",
"   <p>",
"    In contrast to normal physiology, the lowest arterial oxygen saturation and highest PaCO",
"    <sub>",
"     2",
"    </sub>",
"    occur near peak hyperpnea in CSR, suggesting that the level of PaCO",
"    <sub>",
"     2",
"    </sub>",
"    at any given moment reflects the patient's stimulation to breathe and not the effectiveness of ventilation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Comorbidities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cheyne-Stokes respiration is commonly associated with cardiac disease; it can also accompany neurologic disease, sedation, normal sleep, acid-base disturbances, prematurity, and altitude acclimatization [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22520/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. In one study of 42 patients with stable heart failure, 45 percent of patients had more than 20 episodes of apneas or hypopneas per hour of sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22520/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/43/8888?source=see_link\">",
"     \"Cheyne-Stokes breathing and obstructive sleep apnea in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5551029\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic evaluation of suspected sleep-disordered breathing is the same for patients with or without heart failure. An in-laboratory overnight polysomnogram is the gold standard diagnostic test. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/29/44502?source=see_link&amp;anchor=H10#H10\">",
"     \"Central sleep apnea: Risk factors, clinical presentation, and diagnosis\", section on 'Diagnostic evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/43/8888?source=see_link&amp;anchor=H6#H6\">",
"     \"Cheyne-Stokes breathing and obstructive sleep apnea in heart failure\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of CSR focuses on treatment of the underlying cause (eg, optimizing medical therapy of heart failure), but may also include nocturnal positive airway pressure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    supplemental oxygen in selected patients. The management of CSR is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/43/8888?source=see_link&amp;anchor=H8#H8\">",
"     \"Cheyne-Stokes breathing and obstructive sleep apnea in heart failure\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MYXEDEMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoventilation can occur in patients with severe hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22520/abstract/46\">",
"     46",
"    </a>",
"    ]. It probably reflects both respiratory muscle weakness and depression of ventilatory drive [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22520/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/9/23701?source=see_link\">",
"     \"Respiratory function in thyroid disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8566?source=see_link\">",
"     \"Myxedema coma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     STARVATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hypoxic ventilatory response falls approximately 40 percent among normal volunteers following 10 days of 500",
"    <span class=\"nowrap\">",
"     kcal/day",
"    </span>",
"    diet restriction [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22520/abstract/49\">",
"     49",
"    </a>",
"    ]. There is little change in the hypercapnic ventilatory response. Prolonged caloric restriction can have other effects on pulmonary function, including the development of hyperinflation combined with emphysematous radiographic changes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22520/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/62/38890?source=see_link&amp;anchor=H1782633#H1782633\">",
"     \"Anorexia nervosa in adults and adolescents: Medical complications and their management\", section on 'Pulmonary'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     NEUROMUSCULAR DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impairment of the ventilatory response to CO",
"    <sub>",
"     2",
"    </sub>",
"    occurs in patients with a wide variety of neuromuscular diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22520/abstract/51\">",
"     51",
"    </a>",
"    ]. The reduced ventilatory response is due to neuromuscular weakness, and ventilatory drive, as measured by P0.1, is usually well preserved [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22520/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40008?source=see_link\">",
"     \"Control of ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with neuromuscular disease show different first-breath ventilatory responses to graded elastic and resistive loads [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22520/abstract/55\">",
"     55",
"    </a>",
"    ]. These abnormalities in respiratory timing suggest that neuromuscular diseases impair respiratory perception as well as respiratory muscle strength.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DRUGS AFFECTING VENTILATORY DRIVE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of drugs can affect central ventilatory drive. These medications may either depress or stimulate ventilation, and may be useful therapeutically in some clinical situations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Central nervous system depressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several classes of drugs suppress central respiratory drive, including opiates, barbiturates, and benzodiazepines. These medications should be used judiciously in patients with preexisting hypoventilation, but may be useful in patients with hyperventilation secondary to pain, anxiety, or malignant pleural effusion [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22520/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40920?source=see_link\">",
"     \"Pain control in the critically ill adult patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/29/15833?source=see_link\">",
"     \"Sedative-analgesic medications in critically ill patients: Selection, initiation, maintenance, and withdrawal\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Medroxyprogesterone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medroxyprogesterone increases the ventilatory drive in normal males, leading to about a 5 mmHg (0.67 kPa) fall in PaCO",
"    <sub>",
"     2",
"    </sub>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22520/abstract/57\">",
"     57",
"    </a>",
"    ]. The drug has been used to treat patients with excessive polycythemia of high altitude and central hypoventilation syndromes, such as the obesity-hypoventilation syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22520/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29192?source=see_link\">",
"     \"Treatment of the obesity hypoventilation syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Its effectiveness in treating hypercapnia associated with COPD is unclear; reductions in PaCO",
"    <sub>",
"     2",
"    </sub>",
"    are not generally accompanied by improvements in other objective or subjective outcome measures. As an example, one trial of medroxyprogesterone in seven patients with hypercapnic chronic bronchitis found that treatment lowered the mean PaCO",
"    <sub>",
"     2",
"    </sub>",
"    from 51 to 44 mmHg (6.78 to 5.85 kPa), but had no effect upon sensations of dyspnea or 12-minute walking distance [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22520/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Theophylline",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     Theophylline",
"    </a>",
"    increases the hypoxic ventilatory response and prevents the fall in hypoxic ventilatory response that normally occurs after 15 minutes of hypoxemia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22520/abstract/62\">",
"     62",
"    </a>",
"    ]. Like medroxyprogesterone, theophylline may have some utility in the treatment of central hypoventilatory states, but its utility in hypercapnia secondary to obstructive sleep apnea is limited.",
"   </p>",
"   <p>",
"    In a case report,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    was used successfully to treat a woman with diabetes mellitus, neuropathy, and end stage renal disease who had multiple cardiorespiratory arrests secondary to severe Cheyne-Stokes respiration [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22520/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Acetazolamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     Acetazolamide",
"    </a>",
"    , an inhibitor of carbonic anhydrase, has several effects relevant to ventilation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the brain, by blocking CO",
"      <sub>",
"       2",
"      </sub>",
"      conversion to bicarbonate in tissue capillaries,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"       acetazolamide",
"      </a>",
"      can acutely raise local tissue PCO",
"      <sub>",
"       2",
"      </sub>",
"      . Acetazolamide also lowers cerebrospinal fluid bicarbonate in normal individuals at both 3000 and 14,000 feet [",
"      <a class=\"abstract\" href=\"UTD.htm?21/63/22520/abstract/64\">",
"       64",
"      </a>",
"      ]. Locally elevated PCO",
"      <sub>",
"       2",
"      </sub>",
"      and lower pH in the brain would increase central ventilatory drive and lower PaCO",
"      <sub>",
"       2",
"      </sub>",
"      .",
"     </li>",
"     <li>",
"      In the kidney,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"       acetazolamide",
"      </a>",
"      increases retention of hydrogen ion and increases renal excretion of bicarbonate, causing a metabolic acidosis over several hours; the metabolic acidosis further increases respiratory drive.",
"     </li>",
"     <li>",
"      Opposing the effects that promote increased ventilation,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"       acetazolamide",
"      </a>",
"      blocks the reciprocal conversion of bicarbonate to CO",
"      <sub>",
"       2",
"      </sub>",
"      in pulmonary capillaries, thereby impairing the lung's ability to excrete CO",
"      <sub>",
"       2",
"      </sub>",
"      . This could lead to an increase in PaCO",
"      <sub>",
"       2",
"      </sub>",
"      if ventilation remained constant. However, in normal individuals acetazolamide leads to increased minute ventilation resulting in lower end-tidal PCO",
"      <sub>",
"       2",
"      </sub>",
"      , lower PaCO",
"      <sub>",
"       2",
"      </sub>",
"      , and higher PaO",
"      <sub>",
"       2",
"      </sub>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?21/63/22520/abstract/64,65\">",
"       64,65",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    who are able to increase their ventilation will decrease their PaCO",
"    <sub>",
"     2",
"    </sub>",
"    because their increased ventilatory drive will surpass their impaired lung excretion of CO",
"    <sub>",
"     2",
"    </sub>",
"    . In contrast, patients who are unable to augment their ventilation (eg, those with severe COPD) may develop a severe respiratory acidosis on acetazolamide [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22520/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     Acetazolamide",
"    </a>",
"    is effective in the prophylaxis and treatment of acute and chronic mountain sickness [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22520/abstract/67-69\">",
"     67-69",
"    </a>",
"    ]. This effect is likely due to increased ventilation and decreased oxygen desaturation with acetazolamide. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/18/297?source=see_link\">",
"     \"High altitude illness: Physiology, risk factors, and general prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    reduces central sleep apneas in patients with heart failure and Cheyne-Stokes respiration. This was shown in a small cross-over study of 12 patients who had a reduction in episodes of central sleep apnea when acetazolamide was given an hour before bedtime [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22520/abstract/70\">",
"     70",
"    </a>",
"    ]. The efficacy and side effects of long term treatment are unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Antioxidants",
"    </span>",
"    &nbsp;&mdash;&nbsp;A combination of antioxidants &ndash; vitamins E, A, and C for two months,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    for 15 days, and N-acetylcysteine for three days &ndash; increases the sensitivity of the ventilatory response to CO",
"    <sub>",
"     2",
"    </sub>",
"    in normal subjects during hyperoxic unloaded breathing and after resistive breathing [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22520/abstract/71\">",
"     71",
"    </a>",
"    ]. The effect of antioxidants on ventilatory response to CO",
"    <sub>",
"     2",
"    </sub>",
"    in non-hyperoxic conditions or in patients with lung disease is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5550924\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A variety of disorders, including chronic obstructive pulmonary disease, asthma, Ondine's curse, carotid body resection, Cheyne-Stokes respiration, myxedema, starvation, and neuromuscular disease, are associated with abnormal ventilatory control. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some patients with chronic obstructive pulmonary disease (COPD) develop hypercapnia (ie, elevated PaCO",
"      <sub>",
"       2",
"      </sub>",
"      or CO",
"      <sub>",
"       2",
"      </sub>",
"      retention) and hypoxemia. The development of hypercapnia in COPD usually occurs in patients with more severe COPD who also have blunted hypoxic and hypercapnic respiratory drives. Some hypercapnic, hypoxemic patients with COPD develop increased CO",
"      <sub>",
"       2",
"      </sub>",
"      retention when O",
"      <sub>",
"       2",
"      </sub>",
"      is administered. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Chronic obstructive pulmonary disease'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/63/3064?source=see_link&amp;anchor=H9#H9\">",
"       \"Use of oxygen in patients with hypercapnia\", section on 'Hypercapnia in COPD'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Some patients with asthma demonstrate depressed hypoxic and hypercapnic ventilatory responses as well as a reduced perception of dyspnea. These patients appear to be at an increased risk of near fatal asthma exacerbations, characterized by severe hypoxemia and hypercapnia. It is thought that the reduced perception of dyspnea contributes to delays in seeking medical attention during asthma exacerbations. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Asthma'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/26/13735?source=see_link&amp;anchor=H10#H10\">",
"       \"Identifying patients at risk for fatal asthma\", section on 'Poor perception of dyspnea'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The term Ondine's curse has been applied to patients with alveolar hypoventilation due to impaired autonomic control of ventilation, but normal voluntary control. The most common cause is congenital central hypoventilation; other etiologies include brainstem injury or tumor and late-onset central hypoventilation syndrome. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Ondine's curse'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Congenital central hypoventilation syndrome (CCHS) is associated with a nearly absent respiratory response to hypoxia and hypercapnia, no respiratory discomfort during CO",
"      <sub>",
"       2",
"      </sub>",
"      inhalation, mildly elevated arterial carbon dioxide tension (PaCO",
"      <sub>",
"       2",
"      </sub>",
"      ) during wakefulness, and markedly elevated PaCO",
"      <sub>",
"       2",
"      </sub>",
"      during non-REM sleep. CCHS can occur in association with Hirschsprung's disease, a condition characterized by abnormalities of the cholinergic innervation of the gastrointestinal tract. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Congenital central hypoventilation syndrome'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41848?source=see_link\">",
"       \"Congenital aganglionic megacolon (Hirschsprung disease)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cheyne-Stokes respiration (CSR) describes cyclic breathing in which apnea is followed by gradually increasing respiratory frequency and tidal volume (ie, hyperpnea), then gradually decreasing respiratory frequency and tidal volume until the next apneic period. The diagnosis and management of CSR are discussed separately. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Cheyne-stokes respiration'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/43/8888?source=see_link\">",
"       \"Cheyne-Stokes breathing and obstructive sleep apnea in heart failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A variety of drugs can affect central ventilatory drive; central nervous system depressants can decrease ventilatory drive, while medroxyprogesterone,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"       acetazolamide",
"      </a>",
"      , and antioxidants can modestly increase ventilatory drive. However, the clinical use of these drugs to adjust ventilatory drive is limited. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Drugs affecting ventilatory drive'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11123745\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Homayoun Kazemi, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/1\">",
"      Louren&ccedil;o RV, Miranda JM. Drive and performance of the ventilatory apparatus in chronic obstructive lung disease. N Engl J Med 1968; 279:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/2\">",
"      Matthews AW, Howell JB. Assessment of responsiveness to carbon dioxide in patients with chronic airways obstruction by rate of isometric inspiratory pressure development. Clin Sci Mol Med 1976; 50:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/3\">",
"      Javaheri S, Blum J, Kazemi H. Pattern of breathing and carbon dioxide retention in chronic obstructive lung disease. Am J Med 1981; 71:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/4\">",
"      Bradley CA, Fleetham JA, Anthonisen NR. Ventilatory control in patients with hypoxemia due to obstructive lung disease. Am Rev Respir Dis 1979; 120:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/5\">",
"      Lee J, Read J. Effect of oxygen breathing on distribution of pulmonary blood flow in chronic obstructive lung disease. Am Rev Respir Dis 1967; 96:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/6\">",
"      Lenfant C. Arterial-alveolar difference in PCO2 during air and oxygen breathing. J Appl Physiol 1966; 21:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/7\">",
"      Kikuchi Y, Okabe S, Tamura G, et al. Chemosensitivity and perception of dyspnea in patients with a history of near-fatal asthma. N Engl J Med 1994; 330:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/8\">",
"      Rebuck AS, Read J. Patterns of ventilatory response to carbon dioxide during recovery from severe asthma. Clin Sci 1971; 41:13.",
"     </a>",
"    </li>",
"    <li>",
"     Kazemi H, Kanarek DJ. Gas exchange in asthma. In: Status Asthmaticus, Weiss EB (Ed), United Park Press, Baltimore 1978. p.101.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/10\">",
"      Severinghaus, JW, Mitchell, RA. Ondine's curse - failure of respiratory center automaticity while awake. Clin Res 1962; 10:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/11\">",
"      Mellins RB, Balfour HH Jr, Turino GM, Winters RW. Failure of automatic control of ventilation (Ondine's curse). Report of an infant born with this syndrome and review of the literature. Medicine (Baltimore) 1970; 49:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/12\">",
"      Mullan S, Hosobuchi Y. Respiratory hazards of high cervical percutaneous cordotomy. J Neurosurg 1968; 28:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/13\">",
"      Marin-Sanabria EA, Kobayashi N, Miyake S, Kohmura E. Snoring associated with Ondine's curse in a patient with brainstem glioma. J Clin Neurosci 2006; 13:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/14\">",
"      Lassman AB, Mayer SA. Paroxysmal apnea and vasomotor instability following medullary infarction. Arch Neurol 2005; 62:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/15\">",
"      Bogousslavsky J, Khurana R, Deruaz JP, et al. Respiratory failure and unilateral caudal brainstem infarction. Ann Neurol 1990; 28:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/16\">",
"      Idiopathic congenital central hypoventilation syndrome: diagnosis and management. American Thoracic Society. Am J Respir Crit Care Med 1999; 160:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/17\">",
"      Paton JY, Swaminathan S, Sargent CW, Keens TG. Hypoxic and hypercapnic ventilatory responses in awake children with congenital central hypoventilation syndrome. Am Rev Respir Dis 1989; 140:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/18\">",
"      Shannon DC, Marsland DW, Gould JB, et al. Central hypoventilation during quiet sleep in two infants. Pediatrics 1976; 57:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/19\">",
"      Shea SA, Andres LP, Shannon DC, et al. Respiratory sensations in subjects who lack a ventilatory response to CO2. Respir Physiol 1993; 93:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/20\">",
"      Shea SA, Andres LP, Shannon DC, Banzett RB. Ventilatory responses to exercise in humans lacking ventilatory chemosensitivity. J Physiol 1993; 468:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/21\">",
"      Gozal D, Marcus CL, Ward SL, Keens TG. Ventilatory responses to passive leg motion in children with congenital central hypoventilation syndrome. Am J Respir Crit Care Med 1996; 153:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/22\">",
"      Shea SA. Life without ventilatory chemosensitivity. Respir Physiol 1997; 110:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/23\">",
"      Gozal D, Simakajornboon N. Passive motion of the extremities modifies alveolar ventilation during sleep in patients with congenital central hypoventilation syndrome. Am J Respir Crit Care Med 2000; 162:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/24\">",
"      Trang H, Dehan M, Beaufils F, et al. The French Congenital Central Hypoventilation Syndrome Registry: general data, phenotype, and genotype. Chest 2005; 127:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/25\">",
"      Croaker GD, Shi E, Simpson E, et al. Congenital central hypoventilation syndrome and Hirschsprung's disease. Arch Dis Child 1998; 78:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/26\">",
"      Weese-Mayer DE, Silvestri JM, Huffman AD, et al. Case/control family study of autonomic nervous system dysfunction in idiopathic congenital central hypoventilation syndrome. Am J Med Genet 2001; 100:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/27\">",
"      Marazita ML, Maher BS, Cooper ME, et al. Genetic segregation analysis of autonomic nervous system dysfunction in families of probands with idiopathic congenital central hypoventilation syndrome. Am J Med Genet 2001; 100:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/28\">",
"      Gelwane G, Trang H, Carel JC, et al. Intermittent hyperglycemia due to autonomic nervous system dysfunction: a new feature in patients with congenital central hypoventilation syndrome. J Pediatr 2013; 162:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/29\">",
"      Amiel J, Laudier B, Atti&eacute;-Bitach T, et al. Polyalanine expansion and frameshift mutations of the paired-like homeobox gene PHOX2B in congenital central hypoventilation syndrome. Nat Genet 2003; 33:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/30\">",
"      Sasaki A, Kanai M, Kijima K, et al. Molecular analysis of congenital central hypoventilation syndrome. Hum Genet 2003; 114:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/31\">",
"      Weese-Mayer DE, Berry-Kravis EM, Zhou L, et al. Idiopathic congenital central hypoventilation syndrome: analysis of genes pertinent to early autonomic nervous system embryologic development and identification of mutations in PHOX2b. Am J Med Genet A 2003; 123A:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/32\">",
"      Matera I, Bachetti T, Puppo F, et al. PHOX2B mutations and polyalanine expansions correlate with the severity of the respiratory phenotype and associated symptoms in both congenital and late onset Central Hypoventilation syndrome. J Med Genet 2004; 41:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/33\">",
"      Gaultier C, Amiel J, Dauger S, et al. Genetics and early disturbances of breathing control. Pediatr Res 2004; 55:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/34\">",
"      Weese-Mayer DE, Berry-Kravis EM. Genetics of congenital central hypoventilation syndrome: lessons from a seemingly orphan disease. Am J Respir Crit Care Med 2004; 170:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/35\">",
"      Weese-Mayer DE, Rand CM, Berry-Kravis EM, et al. Congenital central hypoventilation syndrome from past to future: model for translational and transitional autonomic medicine. Pediatr Pulmonol 2009; 44:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/36\">",
"      Weese-Mayer DE, Berry-Kravis EM, Ceccherini I, et al. An official ATS clinical policy statement: Congenital central hypoventilation syndrome: genetic basis, diagnosis, and management. Am J Respir Crit Care Med 2010; 181:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/37\">",
"      Patwari PP, Stewart TM, Rand CM, et al. Pupillometry in congenital central hypoventilation syndrome (CCHS): quantitative evidence of autonomic nervous system dysregulation. Pediatr Res 2012; 71:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/38\">",
"      Trochet D, de Pontual L, Straus C, et al. PHOX2B germline and somatic mutations in late-onset central hypoventilation syndrome. Am J Respir Crit Care Med 2008; 177:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/39\">",
"      Winter, B. Surgical treatment of asthma, chronic bronchitis and emphysema by bilateral carotid body resection. Respir Ther 1975; 5:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/40\">",
"      Lugliani R, Whipp BJ, Seard C, Wasserman K. Effect of bilateral carotid-body resection on ventilatory control at rest and during exercise in man. N Engl J Med 1971; 285:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/41\">",
"      Cherniack NS, Longobardo GS. Cheyne-Stokes breathing. An instability in physiologic control. N Engl J Med 1973; 288:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/42\">",
"      Dowell AR, Buckley CE 3rd, Cohen R, et al. Cheyne-Stokes respiration. A review of clinical manifestations and critique of physiological mechanisms. Arch Intern Med 1971; 127:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/43\">",
"      Brown, HW, Plum, F. The neurologic basis of Cheyne-Stokes respiration. Am J Med 1961; 30:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/44\">",
"      Javaheri S. A mechanism of central sleep apnea in patients with heart failure. N Engl J Med 1999; 341:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/45\">",
"      Javaheri S, Parker TJ, Wexler L, et al. Occult sleep-disordered breathing in stable congestive heart failure. Ann Intern Med 1995; 122:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/46\">",
"      Zwillich CW, Pierson DJ, Hofeldt FD, et al. Ventilatory control in myxedema and hypothyroidism. N Engl J Med 1975; 292:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/47\">",
"      NORDQVIST P, DHUNER KG, STENBERG K, ORNDAHL G. Myxoedema coma and carbon dioxide-retention. Acta Med Scand 1960; 166:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/48\">",
"      MASSUMI RA, WINNACKER JL. SEVERE DEPRESSION OF THE RESPIRATORY CENTER IN MYXEDEMA. Am J Med 1964; 36:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/49\">",
"      Doekel RC Jr, Zwillich CW, Scoggin CH, et al. Clinical semi-starvation: depression of hypoxic ventilatory response. N Engl J Med 1976; 295:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/50\">",
"      Coxson HO, Chan IH, Mayo JR, et al. Early emphysema in patients with anorexia nervosa. Am J Respir Crit Care Med 2004; 170:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/51\">",
"      Johnson DC, Kazemi H. Central control of ventilation in neuromuscular disease. Clin Chest Med 1994; 15:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/52\">",
"      B&eacute;gin R, Bureau MA, Lupien L, Lemieux B. Control and modulation of respiration in Steinert's myotonic dystrophy. Am Rev Respir Dis 1980; 121:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/53\">",
"      B&eacute;gin R, Bureau MA, Lupien L, Lemieux B. Control of breathing in Duchenne's muscular dystrophy. Am J Med 1980; 69:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/54\">",
"      Skatrud J, Iber C, McHugh W, et al. Determinants of hypoventilation during wakefulness and sleep in diaphragmatic paralysis. Am Rev Respir Dis 1980; 121:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/55\">",
"      Axen K, Bishop M, Haas F. Respiratory load compensation in neuromuscular disorders. J Appl Physiol 1988; 64:2659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/56\">",
"      Liistro G, Aubert G, Rodenstein DO. Management of sleep apnoea syndrome. Eur Respir J 1995; 8:1751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/57\">",
"      Skatrud JB, Dempsey JA, Kaiser DG. Ventilatory response to medroxyprogesterone acetate in normal subjects: time course and mechanism. J Appl Physiol 1978; 44:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/58\">",
"      Kryger M, McCullough RE, Collins D, et al. Treatment of excessive polycythemia of high altitude with respiratory stimulant drugs. Am Rev Respir Dis 1978; 117:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/59\">",
"      Sutton FD Jr, Zwillich CW, Creagh CE, et al. Progesterone for outpatient treatment of Pickwickian syndrome. Ann Intern Med 1975; 83:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/60\">",
"      Lyons HA, Huang CT. Therapeutic use of progesterone in alveolar hypoventilation associated with obesity. Am J Med 1968; 44:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/61\">",
"      Al-Damluji S. The effect of ventilatory stimulation with medroxyprogesterone on exercise performance and the sensation of dyspnoea in hypercapnic chronic bronchitis. Br J Dis Chest 1986; 80:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/62\">",
"      Igarashi T, Nishimura M, Kobayashi S, et al. Dependency on the rate of change in PaO2 of the ventilatory response to progressive hypoxia. Am J Respir Crit Care Med 1995; 151:1815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/63\">",
"      Pesek CA, Cooley R, Narkiewicz K, et al. Theophylline therapy for near-fatal Cheyne-Stokes respiration. A case report. Ann Intern Med 1999; 130:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/64\">",
"      Kronenberg RS, Cain SM. Effects of acetazolamide and hypoxia on cerebrospinal fluid bicarbonate. J Appl Physiol 1968; 24:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/65\">",
"      Swenson ER, Hughes JM. Effects of acute and chronic acetazolamide on resting ventilation and ventilatory responses in men. J Appl Physiol 1993; 74:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/66\">",
"      Skatrud JB, Dempsey JA. Relative effectiveness of acetazolamide versus medroxyprogesterone acetate in correction of chronic carbon dioxide retention. Am Rev Respir Dis 1983; 127:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/67\">",
"      Forwand SA, Landowne M, Follansbee JN, Hansen JE. Effect of acetazolamide on acute mountain sickness. N Engl J Med 1968; 279:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/68\">",
"      Grissom CK, Roach RC, Sarnquist FH, Hackett PH. Acetazolamide in the treatment of acute mountain sickness: clinical efficacy and effect on gas exchange. Ann Intern Med 1992; 116:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/69\">",
"      Richalet JP, Rivera M, Bouchet P, et al. Acetazolamide: a treatment for chronic mountain sickness. Am J Respir Crit Care Med 2005; 172:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/70\">",
"      Javaheri S. Acetazolamide improves central sleep apnea in heart failure: a double-blind, prospective study. Am J Respir Crit Care Med 2006; 173:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22520/abstract/71\">",
"      Zakynthinos S, Katsaounou P, Karatza MH, et al. Antioxidants increase the ventilatory response to hyperoxic hypercapnia. Am J Respir Crit Care Med 2007; 175:62.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5113 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-9CEA1CDAAA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_63_22520=[""].join("\n");
var outline_f21_63_22520=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5550924\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CHRONIC OBSTRUCTIVE PULMONARY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ASTHMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ONDINE'S CURSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Congenital central hypoventilation syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Late-onset central hypoventilation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CAROTID BODY RESECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CHEYNE-STOKES RESPIRATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Mechanism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Comorbidities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5551029\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MYXEDEMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      STARVATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      NEUROMUSCULAR DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DRUGS AFFECTING VENTILATORY DRIVE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Central nervous system depressants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Medroxyprogesterone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Theophylline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Acetazolamide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Antioxidants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5550924\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11123745\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/5113\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/5113|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/0/43022\" title=\"figure 1\">",
"      Ventilatory response in asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/21/5470\" title=\"figure 2\">",
"      Dyspnea in asthmatics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/62/38890?source=related_link\">",
"      Anorexia nervosa in adults and adolescents: Medical complications and their management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/29/44502?source=related_link\">",
"      Central sleep apnea: Risk factors, clinical presentation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/43/8888?source=related_link\">",
"      Cheyne-Stokes breathing and obstructive sleep apnea in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41848?source=related_link\">",
"      Congenital aganglionic megacolon (Hirschsprung disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40008?source=related_link\">",
"      Control of ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/18/297?source=related_link\">",
"      High altitude illness: Physiology, risk factors, and general prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/26/13735?source=related_link\">",
"      Identifying patients at risk for fatal asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8566?source=related_link\">",
"      Myxedema coma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40920?source=related_link\">",
"      Pain control in the critically ill adult patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/9/23701?source=related_link\">",
"      Respiratory function in thyroid disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/29/15833?source=related_link\">",
"      Sedative-analgesic medications in critically ill patients: Selection, initiation, maintenance, and withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15286?source=related_link\">",
"      Sleep related breathing disorders in adults: Definitions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10087?source=related_link\">",
"      Stroke-related pulmonary complications and abnormal respiratory patterns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29192?source=related_link\">",
"      Treatment of the obesity hypoventilation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/63/3064?source=related_link\">",
"      Use of oxygen in patients with hypercapnia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_63_22521="Clinical manifestations and diagnosis of primary sclerosing cholangitis";
var content_f21_63_22521=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of primary sclerosing cholangitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/63/22521/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/63/22521/contributors\">",
"     Kris V Kowdley, MD, FACP, FACG, FASGE, AGAF",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/63/22521/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/63/22521/contributors\">",
"     Paul Angulo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/63/22521/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/63/22521/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/63/22521/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary sclerosing cholangitis (PSC) is a chronic progressive disorder of unknown etiology that is characterized by inflammation, fibrosis, and stricturing of medium size and large ducts in the intrahepatic and extrahepatic biliary tree (",
"    <a class=\"graphic graphic_picture graphicRef70795 \" href=\"UTD.htm?16/12/16583\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The great majority of cases have underlying ulcerative colitis; the prevalence may be as high as 90 percent when rectal and sigmoid biopsies are routinely obtained [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/3\">",
"     3",
"    </a>",
"    ]. Conversely, it has been estimated that PSC occurs in approximately 5 percent of patients with ulcerative colitis and perhaps less often in those with Crohn's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35334?source=see_link\">",
"     \"Epidemiology and pathogenesis of primary sclerosing cholangitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Continued destruction of bile ducts in PSC leads to end-stage liver disease and portal hypertension. Patients with PSC also may develop a number of other complications, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cholestasis-associated problems",
"     </li>",
"     <li>",
"      Biliary stricture",
"     </li>",
"     <li>",
"      Cholangitis and cholelithiasis",
"     </li>",
"     <li>",
"      Cholangiocarcinoma",
"     </li>",
"     <li>",
"      Colon cancer (in patients with concomitant ulcerative colitis) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/25/40342?source=see_link\">",
"       \"Colorectal cancer and primary sclerosing cholangitis\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic review will discuss the clinical manifestations and diagnosis of PSC and management of complications. Treatment of the liver disease in PSC is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41097?source=see_link\">",
"     \"Treatment of primary sclerosing cholangitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with primary sclerosing cholangitis are asymptomatic at the time of diagnosis, although some may have advanced disease. The disease should be considered in patients with inflammatory bowel disease who have otherwise unexplained abnormal liver biochemical tests, particularly an elevation in serum alkaline phosphatase.",
"   </p>",
"   <p>",
"    Fatigue and pruritus are common features at presentation. Fevers, chills, night sweats, and right upper quadrant pain can also be present. These features may represent episodic bacterial cholangitis from biliary obstruction rather than advanced disease. Liver biochemical tests may worsen during these episodes, but persistent jaundice usually reflects advanced disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver biochemical tests usually demonstrate a cholestatic pattern; elevation of the serum alkaline phosphatase predominates in most patients. The serum alkaline phosphatase and bilirubin may fluctuate substantially, possibly indicating transient blockage of strictured bile ducts by biliary sludge or small stones. The serum aminotransferases are typically less than 300 int.",
"    <span class=\"nowrap\">",
"     unit/L.",
"    </span>",
"    The serum albumin concentration is normal in patients with early stage disease, although those with active inflammatory bowel disease may have hypoalbuminemia.",
"   </p>",
"   <p>",
"    Additional serologic findings in patients with PSC include [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/1\">",
"     1",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35334?source=see_link\">",
"     \"Epidemiology and pathogenesis of primary sclerosing cholangitis\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hypergammaglobulinemia &ndash; 30 percent",
"     </li>",
"     <li>",
"      Increased serum IgM levels &ndash; 40 to 50 percent",
"     </li>",
"     <li>",
"      Atypical perinuclear antineutrophil cytoplasmic antibodies (P-ANCA) &ndash; 30 to 80 percent",
"     </li>",
"     <li>",
"      Human leukocyte antigen DRw52a &ndash; 0 to 100 percent in various reports [",
"      <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/5,6\">",
"       5,6",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of other autoantibodies, including antinuclear, antismooth muscle, anticardiolipin, thyroperoxidase, and rheumatoid factor may also be present, but of uncertain clinical significance. Antimitochondrial antibodies, which are characteristic of primary biliary cirrhosis, are usually absent in PSC. In one study, 71 of 73 (97 percent) patients with PSC were positive for at least one autoantibody while 59 (81 percent) were positive for &ge;3 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/7\">",
"     7",
"    </a>",
"    ]. The presence of autoantibodies did not correlate with disease severity, with the exception of anticardiolipin antibodies, which correlated with the Mayo risk score.",
"   </p>",
"   <p>",
"    Elevated serum IgG4 (a characteristic marker of autoimmune pancreatitis that is seen at lower levels in several other diseases) has been described in patients with PSC [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. In a report of 127 patients with PSC, 12 (9 percent) had values above the upper limit of normal [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Differential diagnosis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40168?source=see_link&amp;anchor=H11#H11\">",
"     \"Autoimmune pancreatitis\", section on 'Serologic testing for IgG4'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hepatic and urinary copper levels are increased and serum ceruloplasmin is reduced in most patients with PSC. However, these findings are not specific, being commonly found in patients who have other forms of chronic cholestatic liver disease. Copper accumulation worsens as the disease progresses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of PSC is established by the demonstration of characteristic multifocal stricturing and dilation of intrahepatic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    extrahepatic bile ducts on cholangiography (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72605 \" href=\"UTD.htm?21/6/21615\">",
"     image 1",
"    </a>",
"    ). Abnormal bile ducts may also be suggested on ultrasound (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81306 graphicRef81312 \" href=\"UTD.htm?10/51/11059\">",
"     image 2A-B",
"    </a>",
"    ), although findings are usually not diagnostic. Magnetic resonance cholangiography may be an alternative to endoscopic cholangiography, particularly if the image quality continues to improve [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23351?source=see_link\">",
"     \"Magnetic resonance cholangiopancreatography\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The biliary strictures may be focal, with normal intervening areas, or diffuse and involve a long segment. Strictures can occur in any part of the biliary tree. In one report of 100 patients, strictures were present in the following distribution [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intrahepatic and extrahepatic bile ducts &ndash; 87 percent",
"     </li>",
"     <li>",
"      Intrahepatic bile ducts alone &ndash; 11 percent",
"     </li>",
"     <li>",
"      Extrahepatic bile ducts alone &ndash; 2 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The gallbladder and cystic duct may also be involved (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59308 \" href=\"UTD.htm?30/22/31073\">",
"     image 3",
"    </a>",
"    ). A study of 286 patients with PSC found one or more gallbladder abnormalities in 41 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/13\">",
"     13",
"    </a>",
"    ]. Gallbladder findings were more common in those with extrahepatic PSC. A gallbladder mass lesion was found in 18 patients (6 percent), ten of which represented gallbladder carcinoma suggesting that cholecystectomy should be performed when such lesions are detected. Similar results have been reported by others [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to the characteristic strictures, shallow ulcerations of the bile ducts may be the only cholangiographic finding in patients with early stage disease. In addition, cholangiography is normal in a small percentage of patients who have a variant of PSC known as \"small-duct primary sclerosing cholangitis\". This variant (sometimes referred to as \"pericholangitis\") is probably a form of PSC involving small caliber bile ducts [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/15\">",
"     15",
"    </a>",
"    ]. It has similar biochemical and histologic features to classic PSC. It appears to have a significantly better prognosis than classic PSC [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/16-18\">",
"     16-18",
"    </a>",
"    ], although it may evolve into classic PSC [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/19\">",
"     19",
"    </a>",
"    ]. Classic PSC developed in only 4 of 27 patients in one series that focused on 27 of 32 patients with small-duct PSC who had undergone repeated cholangiographic examinations after a median of 72 months [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary causes of the cholangiographic findings described above should be considered. These include chronic bacterial cholangitis, infectious or ischemic cholangiopathy, and malignancy.",
"   </p>",
"   <p>",
"    A rare, steroid-responsive disorder involving stricturing of the pancreaticobiliary tract and elevated serum levels of IgG4 has been described that shares clinical and radiographic features with PSC. This disorder has been referred to as sclerosing pancreatocholangitis, autoimmune pancreatitis, and immunoglobulin G4 associated cholangitis. A 2010 guideline issued by the American Association for the Study of Liver Diseases (AASLD) suggests that serum IgG4 be measured in all newly diagnosed patients with PSC [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/20\">",
"     20",
"    </a>",
"    ]. Glucocorticoids can be given to those with clinical, biochemical and imaging features of immunoglobulin G4 associated cholangitis provided that a response can be assessed on imaging and liver biochemistries. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40168?source=see_link\">",
"     \"Autoimmune pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Liver biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A percutaneous liver biopsy may support the diagnosis of PSC, but is rarely diagnostic. We suggest that antibiotics (often",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    ) be given prior to the procedure to minimize the risk of subsequent cholangitis. A 2010 guideline from the AASLD recommends against routine liver biopsy for diagnosis of PSC in patients with typical cholangiographic findings [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/20\">",
"     20",
"    </a>",
"    ]. The AASLD recommends a liver biopsy be performed to diagnose small-duct PSC in patients in whom there is heightened clinical suspicion but who have normal cholangiographic findings.",
"   </p>",
"   <p>",
"    The most specific histologic finding in PSC is fibrous obliteration of small bile ducts, with concentric replacement by connective tissue in an \"onion skin\" pattern (",
"    <a class=\"graphic graphic_picture graphicRef70795 \" href=\"UTD.htm?16/12/16583\">",
"     picture 1",
"    </a>",
"    ). More often, histologic abnormalities in PSC are nonspecific and are similar to those in primary biliary cirrhosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41641?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and natural history of primary biliary cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The histologic findings initially involve the portal triads, but expand into the hepatic parenchyma as the disease progresses. As a result, liver biopsy is helpful for staging the disease and determining prognosis. The staging system used most commonly in PSC is similar to that used in primary biliary cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stage I &ndash; Enlargement, edema, and scarring of the portal triads, and mononuclear cell infiltration with some piecemeal necrosis and damage to isolated bile ducts. Proliferation of interlobular bile ducts with mononuclear and polymorphonuclear cells may also be present, although the inflammation is usually less dense than in primary biliary cirrhosis.",
"     </li>",
"     <li>",
"      Stage II &ndash; Expansion of portal triads with fibrosis extending into the surrounding parenchyma",
"     </li>",
"     <li>",
"      Stage III &ndash; Bridging fibrosis",
"     </li>",
"     <li>",
"      Stage IV &ndash; Cirrhosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;PSC is usually a progressive disorder that ultimately leads to complications of cholestasis and hepatic failure. Median survival without liver transplantation after diagnosis is 10 to 12 years [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. Survival is significantly worse for patients who are symptomatic at the time of diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several groups have studied variables that appear to predict prognosis in PSC. These include age, histological stage, hepatomegaly, splenomegaly, serum alkaline phosphatase, serum bilirubin, the presence of a dominant bile duct stricture, concurrent inflammatory bowel disease (IBD), and Candida in bile [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/23-28\">",
"     23-28",
"    </a>",
"    ]. One study, for example, found that approximately 90 percent of those with stage II disease would be expected to progress to bridging fibrosis or cirrhosis, while approximately one-half of those who had already developed bridging fibrosis were expected to develop cirrhosis within five years. This was a predicted progression based on their model [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Concurrent IBD may also be associated with a poorer prognosis. In a study that compared 60 patients with PSC and IBD with 19 patients with PSC but without IBD, the presence of IBD was associated with a lower median age at presentation (46 versus 64 years), the development of serious malignant complications (23 versus 0 percent), and lower liver transplant-free survival (57 versus 84 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/27\">",
"     27",
"    </a>",
"    ]. A second study of 222 patients with PSC (167 with ulcerative colitis [UC] and 55 without UC) also found that patients with PSC associated with UC were diagnosed at a younger age than those without UC (median age at presentation 38 versus 47 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/30\">",
"     30",
"    </a>",
"    ]. It also found higher rates of dysplasia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    colon cancer among patients with UC (33 versus 2 percent). However, the presence of UC was not associated with death or liver transplantation after adjusting for sex, Mayo risk score (see below), and year of diagnosis.",
"   </p>",
"   <p>",
"    Variables associated with prognosis have been incorporated in a well-validated statistical model (the Mayo risk score [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/31\">",
"     31",
"    </a>",
"    ]) (",
"    <a class=\"graphic graphic_table graphicRef54210 \" href=\"UTD.htm?13/50/14123\">",
"     table 1",
"    </a>",
"    ). The components of the Mayo risk score include age, serum bilirubin, serum albumin, serum AST, and history of variceal bleeding. The calculation of this risk score correlates well with observed survival and is useful in assessing prognosis and determining timing for liver transplantation, although prioritization for transplantation is based upon the MELD score. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15770?source=see_link\">",
"     \"Model for End-stage Liver Disease (MELD)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CHOLESTASIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complications common to all of the chronic cholestatic liver diseases such as PSC include fatigue, pruritus, steatorrhea, fat-soluble vitamin deficiencies (A, D, E, and K), and metabolic bone disease. Little is known about the pathogenesis of fatigue; nevertheless, it may become quite debilitating, and is one of the prime indications for liver transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Pruritus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pruritus is a common symptom of PSC which can be extremely disabling, leading to severe excoriations and a decreased quality of life. The pathogenesis of pruritus in PSC, as in other disorders which cause cholestasis, is not clear. Several hypotheses have been proposed, including bile acid accumulation and endogenous opioids [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. Treatment should be based upon the severity of the pruritus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23863?source=see_link\">",
"     \"Pruritus associated with cholestasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Steatorrhea and vitamin deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Steatorrhea with concomitant fat soluble vitamin deficiency in patients with PSC is generally thought to be due to decreased secretion of conjugated bile acids into the small intestine [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. However, associated conditions that may coexist with PSC, such as chronic pancreatitis and celiac disease, may also contribute to the genesis of steatorrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]; these disorders should be considered in the differential diagnosis of steatorrhea in a patient with PSC who has no jaundice or evidence of cirrhosis by histology [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vitamin A deficiency has been reported in up to 82 percent of patients with advanced PSC, occasionally accompanied by night blindness [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/41\">",
"     41",
"    </a>",
"    ]. In addition, vitamin D and vitamin E deficiencies occur in approximately one-half of those with advanced disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/41\">",
"     41",
"    </a>",
"    ]. Thus, patients with PSC should be screened for fat soluble vitamin deficiencies by determination of the prothrombin time (vitamin K) and serum levels of vitamins A, D, and E. Supplemental therapy should be administered as necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Metabolic bone disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metabolic bone disease, in particular osteoporosis, is a complication of advanced PSC, with radiologic and histologic evidence of osteopenia in the lumbar spine, iliac crest, and femur [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. An illustrative study included 237 patients who underwent bone density testing every year for ten years [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/45\">",
"     45",
"    </a>",
"    ]. Osteoporosis (defined as a T-score less than -2.5) was detected in 15 percent of patients (24 times more commonly than expected in an age-, sex-, and ethnicity-matched general population). Risk factors included age older than 54 years, body mass index &le;24",
"    <span class=\"nowrap\">",
"     kg/m(2),",
"    </span>",
"    and the presence of inflammatory bowel disease for &ge;19 years. Osteoporosis was present in 75 percent of patients with all three risk factors compared with only 3 percent of those without any risk factors. In another report, bone density was measured in 30 patients with advanced PSC (group 1) and 18 patients with newly diagnosed disease (group 2) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/42\">",
"     42",
"    </a>",
"    ]. Mean bone mineral density was significantly reduced in group 1 compared with age-matched and sex-matched controls (0.97 versus 1.25",
"    <span class=\"nowrap\">",
"     gm/cm2);",
"    </span>",
"    in 15 of the 30 patients, bone density was below the fracture threshold. In contrast, bone mineral density in group 2 was not significantly different from controls, and no patient was below the fracture threshold.",
"   </p>",
"   <p>",
"    Patients with PSC are also prone to develop fractures after liver transplantation, even in the absence of metabolic bone disease, due to immobilization and concomitant therapy with glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29561?source=see_link\">",
"     \"Osteoporosis after solid organ or stem cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathogenesis of bone disease in PSC and other chronic cholestatic liver diseases (eg, primary biliary cirrhosis) is unknown. Bone disease in patients with PSC is due to",
"    <span class=\"nowrap\">",
"     osteopenia/osteoporosis",
"    </span>",
"    rather than osteomalacia, and thus, malabsorption of vitamin D or low serum vitamin D concentration is not the cause in most cases. Furthermore, vitamin repletion in the minority of cases with low serum levels does not reduce either the presence or severity of osteoporosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/47\">",
"     47",
"    </a>",
"    ]. The vast majority of patients with PSC suffer from IBD. IBD increases the risk of bone disease and treatment with glucocorticoids increases the rate of bone loss and the risk of fractures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/54/30569?source=see_link\">",
"     \"Metabolic bone disease in inflammatory bowel disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has also been proposed that a toxin or toxins retained because of cholestasis prevents the osteoblast from functioning normally, resulting in decreased bone formation; unconjugated bilirubin [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/48\">",
"     48",
"    </a>",
"    ], copper [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/49\">",
"     49",
"    </a>",
"    ], and bile salts [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/49\">",
"     49",
"    </a>",
"    ] have all been implicated as potential toxins [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29830?source=see_link\">",
"     \"Metabolic bone disease in primary biliary cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radiologic techniques such as dual photon absorptiometry are superior to traditional serum and urinary markers of bone loss for diagnosing osteopenia in patients with PSC. The axial skeleton (eg, trabecular bone of the lumbar spine) is affected more commonly than the appendicular skeleton (cortical bone) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/49\">",
"     49",
"    </a>",
"    ]. A 2010 guideline from the AASLD recommends bone density examinations at diagnosis and every two to three years thereafter [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/55/11128?source=see_link\">",
"     \"Diagnosis and evaluation of osteoporosis in postmenopausal women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although few studies have specifically addressed the treatment of bone disease in PSC, management principles are similar to those in primary biliary cirrhosis. Calcium supplementation and measurement of vitamin D levels are generally recommended. A 2010 guideline from the AASLD suggests use of calcium (1.0 to 1.5 g daily in divided doses) and vitamin D (1000 int. unit daily) in patients with hepatic osteopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/20\">",
"     20",
"    </a>",
"    ]. For patients with more significant loss of bone density, bisphosphonate therapy may also be beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29830?source=see_link\">",
"     \"Metabolic bone disease in primary biliary cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DOMINANT BILIARY STRICTURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Up to 60 percent of patients with PSC develop a dominant stricture in the intrahepatic or extrahepatic biliary tree [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/25,40,51-53\">",
"     25,40,51-53",
"    </a>",
"    ]. One definition of a dominant stricture is a stenosis with a diameter of &le;1.5 mm in the common bile duct or &le;1 mm in the hepatic ducts [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/52,54\">",
"     52,54",
"    </a>",
"    ]. Strictures can occur at the biliary hilum or anywhere along the common hepatic or common bile ducts [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/55\">",
"     55",
"    </a>",
"    ]. Patients typically present with evidence of mechanical biliary obstruction manifested by jaundice, pruritus, ascending cholangitis, and malabsorption. This presentation is difficult to distinguish from that of cholangiocarcinoma. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Cholangiocarcinoma'",
"    </a>",
"    below.) Thus, if a dominant stricture is identified, cytologic brushings of the stricture should be performed to exclude malignancy.",
"   </p>",
"   <p>",
"    Medical therapy to treat biliary strictures has been ineffective. Nonsurgical modalities to relieve biliary obstruction, such as endoscopically or radiologically guided balloon dilation of strictures or placement of prosthetic stents across strictures, should be attempted initially. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41097?source=see_link\">",
"     \"Treatment of primary sclerosing cholangitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CHOLANGITIS AND CHOLELITHIASIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Choledocholithiasis and cholelithiasis, due to cholesterol",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pigment stones, may be present in up to one-third of patients with PSC [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/56\">",
"     56",
"    </a>",
"    ]. Ultrasonography can identify biliary obstruction but has a low sensitivity for determining its cause (eg, stricture, stone, or neoplasm). Thus, cholangiography should be used to detect reversible causes of biliary obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/40,57\">",
"     40,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gallstones in patients with PSC are treated the same way as in other patients. Attempts are made to remove gallstones only if they are causing obstruction of the major bile ducts; incidental gallstones in the gallbladder are not treated unless the clinical scenario dictates that they need to be removed.",
"   </p>",
"   <p>",
"    Bacterial cholangitis can occur in patients with PSC. The risk is greatest after endoscopic or surgical manipulation (including liver biopsy), but cholangitis can also develop spontaneously, particularly in patients with bile duct stones or obstructing strictures [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/57-59\">",
"     57-59",
"    </a>",
"    ]. Biliary candida infections have also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24790?source=see_link\">",
"     \"Acute cholangitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13044254\">",
"    <span class=\"h1\">",
"     HEPATOBILIARY CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with PSC are at increased risk for cholangiocarcinoma, gallbladder cancer, and, in patients with cirrhosis, hepatocellular carcinoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Cholangiocarcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with PSC have a 10 to 15 percent lifetime risk of developing cholangiocarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/1,61\">",
"     1,61",
"    </a>",
"    ]. The annual incidence in the setting of PSC has been estimated to be 1.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/62\">",
"     62",
"    </a>",
"    ]. In a series of 161 patients seen at the Mayo clinic, 7 percent developed cholangiocarcinoma during a mean follow-up of 11.5 years [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/63\">",
"     63",
"    </a>",
"    ]. Patients with normalization or near normalization of their alkaline phosphatase may be at decreased risk for developing cholangiocarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/64,65\">",
"     64,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk factors that have been identified in one or more studies include the presence of inflammatory bowel disease, cirrhosis, variceal bleeding, a dominant stricture (in patients who also have inflammatory bowel disease) and regular alcohol consumption [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/63,66-68\">",
"     63,66-68",
"    </a>",
"    ]. However, the strength of these associations remains uncertain.",
"   </p>",
"   <p>",
"    The development of cholangiocarcinoma is often heralded by rapid clinical deterioration with jaundice, weight loss, and abdominal discomfort [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/61\">",
"     61",
"    </a>",
"    ]. The presence of progressive biliary dilatation in the setting of a dominant stricture should also raise a strong suspicion of cholangiocarcinoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/43/40633?source=see_link\">",
"     \"Clinical manifestations and diagnosis of cholangiocarcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Diagnosis and screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of cholangiocarcinoma can be extremely difficult in patients with PSC. In an illustrative study, 10 percent of patients with PSC undergoing liver transplantation had an unsuspected cholangiocarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/69\">",
"     69",
"    </a>",
"    ]. Delayed diagnosis often results in the discovery of tumors at an advanced stage when they cannot be resected for cure. As previously mentioned, it is also difficult to distinguish a dominant stricture from a cholangiocarcinoma, even with imaging, endoscopic biopsy, and cytology.",
"   </p>",
"   <p>",
"    The tests used to make the diagnosis include biliary brush cytology, endobiliary biopsy, computed tomography (CT) or magnetic resonance cholangiopancreatography (MRI) scanning, and serum tumor markers such as CEA or CA 19-9 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/70-72\">",
"     70-72",
"    </a>",
"    ].All of these studies have limitations, and none has been shown to be beneficial for screening. However, because of the high incidence of cholangiocarcinoma in patients with PSC, some have argued for annual screening with imaging studies and a serum CA 19-9 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/73\">",
"     73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/43/40633?source=see_link\">",
"     \"Clinical manifestations and diagnosis of cholangiocarcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19816?source=see_link\">",
"     \"Endoscopic methods for the diagnosis of pancreatobiliary neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While no studies have been performed that demonstrate a benefit in patient outcomes with screening using serum tumor markers, imaging studies, or cholangiographic brush cytology, given the high incidence of cholangiocarcinoma, we suggest annual screening for cholangiocarcinoma with either ultrasound or MRI with magnetic resonance cholangiopancreatography (MRCP), plus measurement of a serum CA 19-9. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41097?source=see_link\">",
"     \"Treatment of primary sclerosing cholangitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of cholangiocarcinoma portends a poor prognosis in patients with advanced PSC; only 10 percent of patients survived two years in one report [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/40\">",
"     40",
"    </a>",
"    ]. Liver transplantation has been a disappointment in the treatment of cholangiocarcinoma, with significantly lower patient survival due to recurrent disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/69,74\">",
"     69,74",
"    </a>",
"    ]. Thus, most transplant centers are not transplanting these patients outside of study protocols. The poor prognosis has led to the suggestion for earlier liver transplantation in patients with PSC before cholangiocarcinoma has a chance to develop.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13044278\">",
"    <span class=\"h2\">",
"     Gallbladder cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of gallbladder cancer among patients with PSC is estimated to be 3 to 14 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/73\">",
"     73",
"    </a>",
"    ]. Both the American Association for the Study of Liver Diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/20\">",
"     20",
"    </a>",
"    ] and the European Association for the Study of the Liver [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/75\">",
"     75",
"    </a>",
"    ] recommend annual screening for gallbladder cancer using ultrasound. However, MRI with MRCP may permit screening for both gallbladder cancer and cholangiocarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22521/abstract/73\">",
"     73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/57/13209?source=see_link&amp;anchor=H23#H23\">",
"     \"Gallbladder polyps and cholesterolosis\", section on 'Polyps along with gallstones or primary sclerosing cholangitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13044911\">",
"    <span class=\"h2\">",
"     Hepatocellular carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with PSC and cirrhosis are at increased risk for hepatocellular carcinoma and should undergo screening. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/6/28778?source=see_link&amp;anchor=H61643928#H61643928\">",
"     \"Prevention of hepatocellular carcinoma and recommendations for surveillance in adults with chronic liver disease\", section on 'Patients with cirrhosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     COLON CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with both PSC and ulcerative colitis have an increased risk of colon cancer and progression of neoplastic transformation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/25/40342?source=see_link\">",
"     \"Colorectal cancer and primary sclerosing cholangitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The majority of patients with primary sclerosing cholangitis (PSC) are asymptomatic at the time of diagnosis, although some may have advanced disease. The disease should be considered in patients with inflammatory bowel disease who have otherwise unexplained abnormal liver biochemical tests, particularly an elevation in serum alkaline phosphatase. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of PSC is established by the demonstration of characteristic multifocal stricturing and dilation of intrahepatic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      extrahepatic bile ducts on cholangiography (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef72605 \" href=\"UTD.htm?21/6/21615\">",
"       image 1",
"      </a>",
"      ) and exclusion of other disorders that can produce a similar radiologic picture. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications of PSC include systemic and metabolic complications related to cholestasis, cholangitis, cholelithiasis, cholangiocarcinoma, gallbladder cancer, and colon cancer.",
"     </li>",
"     <li>",
"      PSC is usually a progressive disorder that ultimately leads to complications of cholestasis and hepatic failure. Median survival without liver transplantation after diagnosis is approximately 12 years. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest screening for cholangiocarcinoma and gallbladder cancer in patients with PSC. (See",
"      <a class=\"local\" href=\"#H13044254\">",
"       'Hepatobiliary cancer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with PSC and inflammatory bowel disease have an increased risk of colon cancer, and should be enrolled in colonoscopic surveillance programs. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/25/40342?source=see_link\">",
"       \"Colorectal cancer and primary sclerosing cholangitis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3396720559\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author and UpToDate would like to thank Dr. Bruce Tung, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/1\">",
"      Lee YM, Kaplan MM. Primary sclerosing cholangitis. N Engl J Med 1995; 332:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/2\">",
"      Angulo P, Lindor KD. Primary sclerosing cholangitis. Hepatology 1999; 30:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/3\">",
"      Tung BY, Brentnall T, Kowdley KV, et al. Diagnosis and prevalence of ulcerative colitis in patients with sclerosing cholangitis (abstract). Hepatology 1996; 24:169A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/4\">",
"      Rasmussen HH, Fallingborg JF, Mortensen PB, et al. Hepatobiliary dysfunction and primary sclerosing cholangitis in patients with Crohn's disease. Scand J Gastroenterol 1997; 32:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/5\">",
"      Zetterquist H, Broom&eacute; U, Einarsson K, Olerup O. HLA class II genes in primary sclerosing cholangitis and chronic inflammatory bowel disease: no HLA-DRw52a association in Swedish patients with sclerosing cholangitis. Gut 1992; 33:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/6\">",
"      Prochazka EJ, Terasaki PI, Park MS, et al. Association of primary sclerosing cholangitis with HLA-DRw52a. N Engl J Med 1990; 322:1842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/7\">",
"      Angulo P, Peter JB, Gershwin ME, et al. Serum autoantibodies in patients with primary sclerosing cholangitis. J Hepatol 2000; 32:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/8\">",
"      Mendes FD, Jorgensen R, Keach J, et al. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol 2006; 101:2070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/9\">",
"      Hirano K, Kawabe T, Yamamoto N, et al. Serum IgG4 concentrations in pancreatic and biliary diseases. Clin Chim Acta 2006; 367:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/10\">",
"      Berstad AE, Aabakken L, Smith HJ, et al. Diagnostic accuracy of magnetic resonance and endoscopic retrograde cholangiography in primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2006; 4:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/11\">",
"      Moff SL, Kamel IR, Eustace J, et al. Diagnosis of primary sclerosing cholangitis: a blinded comparative study using magnetic resonance cholangiography and endoscopic retrograde cholangiography. Gastrointest Endosc 2006; 64:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/12\">",
"      Dave M, Elmunzer BJ, Dwamena BA, Higgins PD. Primary sclerosing cholangitis: meta-analysis of diagnostic performance of MR cholangiopancreatography. Radiology 2010; 256:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/13\">",
"      Said K, Glaumann H, Bergquist A. Gallbladder disease in patients with primary sclerosing cholangitis. J Hepatol 2008; 48:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/14\">",
"      Buckles DC, Lindor KD, Larusso NF, et al. In primary sclerosing cholangitis, gallbladder polyps are frequently malignant. Am J Gastroenterol 2002; 97:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/15\">",
"      Wee A, Ludwig J. Pericholangitis in chronic ulcerative colitis: primary sclerosing cholangitis of the small bile ducts? Ann Intern Med 1985; 102:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/16\">",
"      Broom&eacute; U, Glaumann H, Lindst&ouml;m E, et al. Natural history and outcome in 32 Swedish patients with small duct primary sclerosing cholangitis (PSC). J Hepatol 2002; 36:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/17\">",
"      Angulo P, Maor-Kendler Y, Lindor KD. Small-duct primary sclerosing cholangitis: a long-term follow-up study. Hepatology 2002; 35:1494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/18\">",
"      Bj&ouml;rnsson E, Olsson R, Bergquist A, et al. The natural history of small-duct primary sclerosing cholangitis. Gastroenterology 2008; 134:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/19\">",
"      Bj&ouml;rnsson E, Boberg KM, Cullen S, et al. Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis. Gut 2002; 51:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/20\">",
"      Chapman R, Fevery J, Kalloo A, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010; 51:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/21\">",
"      Ludwig J, Barham SS, LaRusso NF, et al. Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hepatology 1981; 1:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/22\">",
"      Wiesner RH, Grambsch PM, Dickson ER, et al. Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology 1989; 10:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/23\">",
"      Farrant JM, Hayllar KM, Wilkinson ML, et al. Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology 1991; 100:1710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/24\">",
"      Broom&eacute; U, Olsson R, L&ouml;&ouml;f L, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996; 38:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/25\">",
"      Tischendorf JJ, Hecker H, Kr&uuml;ger M, et al. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: A single center study. Am J Gastroenterol 2007; 102:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/26\">",
"      Rudolph G, Gotthardt D, Kl&ouml;ters-Plachky P, et al. Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis. J Hepatol 2009; 51:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/27\">",
"      Ngu JH, Gearry RB, Wright AJ, Stedman CA. Inflammatory bowel disease is associated with poor outcomes of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2011; 9:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/28\">",
"      Lindstrom L, Bomberg KM, Ingalill FL. A reduction in alkaline phosphatase levels is associated to improved prognosis in primary sclerosing cholangitis: A 14 year follow up of the Scandinavian ursodeoxycholic acid trial. Hepatology 2012; :247A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/29\">",
"      Angulo P, Larson DR, Therneau TM, et al. Time course of histological progression in primary sclerosing cholangitis. Am J Gastroenterol 1999; 94:3310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/30\">",
"      Navaneethan U, Venkatesh PG, Lashner BA, et al. The Impact of ulcerative colitis on the long-term outcome of patients with primary sclerosing cholangitis. Aliment Pharmacol Ther 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/31\">",
"      Kim WR, Therneau TM, Wiesner RH, et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc 2000; 75:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/32\">",
"      Bergasa NV, Jones EA. The pruritus of cholestasis: potential pathogenic and therapeutic implications of opioids. Gastroenterology 1995; 108:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/33\">",
"      Jones EA, Bergasa NV. Why do cholestatic patients itch? Gut 1996; 38:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/34\">",
"      Bernstein JE, Swift R. Relief of intractable pruritus with naloxone. Arch Dermatol 1979; 115:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/35\">",
"      Kaplan MM. Medical approaches to primary sclerosing cholangitis. Semin Liver Dis 1991; 11:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/36\">",
"      Lanspa SJ, Chan AT, Bell JS 3rd, et al. Pathogenesis of steatorrhea in primary biliary cirrhosis. Hepatology 1985; 5:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/37\">",
"      Hay JE, Wiesner RH, Shorter RG, et al. Primary sclerosing cholangitis and celiac disease. A novel association. Ann Intern Med 1988; 109:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/38\">",
"      B&oslash;rkje B, Vetvik K, Odegaard S, et al. Chronic pancreatitis in patients with sclerosing cholangitis and ulcerative colitis. Scand J Gastroenterol 1985; 20:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/39\">",
"      Epstein O, Chapman RW, Lake-Bakaar G, et al. The pancreas in primary biliary cirrhosis and primary sclerosing cholangitis. Gastroenterology 1982; 83:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/40\">",
"      Wiesner RH. Current concepts in primary sclerosing cholangitis. Mayo Clin Proc 1994; 69:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/41\">",
"      Jorgensen RA, Lindor KD, Sartin JS, et al. Serum lipid and fat-soluble vitamin levels in primary sclerosing cholangitis. J Clin Gastroenterol 1995; 20:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/42\">",
"      Hay JE, Lindor KD, Wiesner RH, et al. The metabolic bone disease of primary sclerosing cholangitis. Hepatology 1991; 14:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/43\">",
"      Steinberg KK, Bonkovsky HL, Caudill SP, et al. Osteocalcin and bone alkaline phosphatase in the serum of women with liver disease. Ann Clin Lab Sci 1991; 21:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/44\">",
"      Bonkovsky HL, Hawkins M, Steinberg K, et al. Prevalence and prediction of osteopenia in chronic liver disease. Hepatology 1990; 12:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/45\">",
"      Angulo P, Grandison GA, Fong DG, et al. Bone disease in patients with primary sclerosing cholangitis. Gastroenterology 2011; 140:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/46\">",
"      Arnold JC, Hauser D, Ziegler R, et al. Bone disease after liver transplantation. Transplant Proc 1992; 24:2709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/47\">",
"      Herlong HF, Recker RR, Maddrey WC. Bone disease in primary biliary cirrhosis: histologic features and response to 25-hydroxyvitamin D. Gastroenterology 1982; 83:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/48\">",
"      Janes CH, Dickson ER, Okazaki R, et al. Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice. J Clin Invest 1995; 95:2581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/49\">",
"      Gua&ntilde;abens N, Par&eacute;s A, Mari&ntilde;oso L, et al. Factors influencing the development of metabolic bone disease in primary biliary cirrhosis. Am J Gastroenterol 1990; 85:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/50\">",
"      Gua&ntilde;abens N, Par&eacute;s A, Ros I, et al. Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. Am J Gastroenterol 2003; 98:2268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/51\">",
"      Skolkin MD, Alspaugh JP, Casarella WJ, et al. Sclerosing cholangitis: palliation with percutaneous cholangioplasty. Radiology 1989; 170:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/52\">",
"      Stiehl A, Rudolph G, Kl&ouml;ters-Plachky P, et al. Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. J Hepatol 2002; 36:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/53\">",
"      Okolicsanyi L, Fabris L, Viaggi S, et al. Primary sclerosing cholangitis: clinical presentation, natural history and prognostic variables: an Italian multicentre study. The Italian PSC Study Group. Eur J Gastroenterol Hepatol 1996; 8:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/54\">",
"      Bj&ouml;rnsson E, Lindqvist-Ottosson J, Asztely M, Olsson R. Dominant strictures in patients with primary sclerosing cholangitis. Am J Gastroenterol 2004; 99:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/55\">",
"      Harnois DM, Lindor KD. Primary sclerosing cholangitis: evolving concepts in diagnosis and treatment. Dig Dis 1997; 15:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/56\">",
"      Brandt DJ, MacCarty RL, Charboneau JW, et al. Gallbladder disease in patients with primary sclerosing cholangitis. AJR Am J Roentgenol 1988; 150:571.",
"     </a>",
"    </li>",
"    <li>",
"     Wienser, RH, Porayko, MK, LaRusso, NF, Ludwig, J. Diseases of the Liver, 7th ed, Schiff, L, Schiff, ER (Eds), JB Lippincott, Philadelphia 1993. p.411.",
"    </li>",
"    <li>",
"     Vierling, JM. Hepatobiliary complications of ulcerative colitis and Crohn's disease. In: Hepatology: A Textbook of Liver Disease, Vol 2, Zakim, D, Boyer, TD (Eds), WB Saunders, Philadelphia 1996. p.1366.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/59\">",
"      Porayko MK, LaRusso NF, Wiesner RH. Primary sclerosing cholangitis: a progressive disease? Semin Liver Dis 1991; 11:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/60\">",
"      Kulaksiz H, Rudolph G, Kloeters-Plachky P, et al. Biliary candida infections in primary sclerosing cholangitis. J Hepatol 2006; 45:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/61\">",
"      Rosen CB, Nagorney DM, Wiesner RH, et al. Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann Surg 1991; 213:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/62\">",
"      Bergquist A, Ekbom A, Olsson R, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002; 36:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/63\">",
"      Burak K, Angulo P, Pasha TM, et al. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 2004; 99:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/64\">",
"      Al Mamari S, Djordjevic J, Halliday JS, Chapman RW. Improvement of serum alkaline phosphatase to &lt;1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol 2013; 58:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/65\">",
"      Stanich PP, Bj&ouml;rnsson E, Gossard AA, et al. Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. Dig Liver Dis 2011; 43:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/66\">",
"      Rudolph G, Gotthardt D, Kloeters-Plachky P, et al. In PSC with dominant bile duct stenosis, IBD is associated with an increase of carcinomas and reduced survival. J Hepatol 2010; 53:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/67\">",
"      Bergquist A, Glaumann H, Persson B, Broom&eacute; U. Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study. Hepatology 1998; 27:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/68\">",
"      Chalasani N, Baluyut A, Ismail A, et al. Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study. Hepatology 2000; 31:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/69\">",
"      Marsh JW Jr, Iwatsuki S, Makowka L, et al. Orthotopic liver transplantation for primary sclerosing cholangitis. Ann Surg 1988; 207:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/70\">",
"      Nichols JC, Gores GJ, LaRusso NF, et al. Diagnostic role of serum CA 19-9 for cholangiocarcinoma in patients with primary sclerosing cholangitis. Mayo Clin Proc 1993; 68:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/71\">",
"      Siqueira E, Schoen RE, Silverman W, et al. Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. Gastrointest Endosc 2002; 56:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/72\">",
"      Boberg KM, Jebsen P, Clausen OP, et al. Diagnostic benefit of biliary brush cytology in cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol 2006; 45:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/73\">",
"      Razumilava N, Gores GJ, Lindor KD. Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology 2011; 54:1842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/74\">",
"      Calne R, Yamanoi A, Oura S, Kawamura M. Liver transplantation for hepatocarcinoma. Surg Today 1993; 23:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22521/abstract/75\">",
"      European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009; 51:237.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 660 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-41.78.124.10-D5AC4AD6BF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_63_22521=[""].join("\n");
var outline_f21_63_22521=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Liver biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CHOLESTASIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Pruritus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Steatorrhea and vitamin deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Metabolic bone disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DOMINANT BILIARY STRICTURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CHOLANGITIS AND CHOLELITHIASIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13044254\">",
"      HEPATOBILIARY CANCER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Cholangiocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Diagnosis and screening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13044278\">",
"      Gallbladder cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13044911\">",
"      Hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      COLON CANCER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3396720559\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/660\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/660|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?21/6/21615\" title=\"diagnostic image 1\">",
"      Intrahepatic PSC ERCP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?43/6/44143\" title=\"diagnostic image 2A\">",
"      PSC liver US",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?5/54/5999\" title=\"diagnostic image 2B\">",
"      Extrahepatic PSC US",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?30/22/31073\" title=\"diagnostic image 3\">",
"      PSC of gallbladder US",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/660|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/12/16583\" title=\"picture 1\">",
"      Bile duct injury PSC Light",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/660|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/50/14123\" title=\"table 1\">",
"      Mayo model survival PSC",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24790?source=related_link\">",
"      Acute cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40168?source=related_link\">",
"      Autoimmune pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/43/40633?source=related_link\">",
"      Clinical manifestations and diagnosis of cholangiocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41641?source=related_link\">",
"      Clinical manifestations, diagnosis, and natural history of primary biliary cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/25/40342?source=related_link\">",
"      Colorectal cancer and primary sclerosing cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/55/11128?source=related_link\">",
"      Diagnosis and evaluation of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19816?source=related_link\">",
"      Endoscopic methods for the diagnosis of pancreatobiliary neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35334?source=related_link\">",
"      Epidemiology and pathogenesis of primary sclerosing cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/57/13209?source=related_link\">",
"      Gallbladder polyps and cholesterolosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23351?source=related_link\">",
"      Magnetic resonance cholangiopancreatography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/54/30569?source=related_link\">",
"      Metabolic bone disease in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29830?source=related_link\">",
"      Metabolic bone disease in primary biliary cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15770?source=related_link\">",
"      Model for End-stage Liver Disease (MELD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29561?source=related_link\">",
"      Osteoporosis after solid organ or stem cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/6/28778?source=related_link\">",
"      Prevention of hepatocellular carcinoma and recommendations for surveillance in adults with chronic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23863?source=related_link\">",
"      Pruritus associated with cholestasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41097?source=related_link\">",
"      Treatment of primary sclerosing cholangitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_63_22522="Overview of cryoglobulins and cryoglobulinemia";
var content_f21_63_22522=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of cryoglobulins and cryoglobulinemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/63/22522/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/63/22522/contributors\">",
"     Stanford L Peng, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/63/22522/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/63/22522/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/63/22522/contributors\">",
"     Mark H Wener, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/63/22522/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/63/22522/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/63/22522/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Precipitation of blood proteins at temperatures lower than 37&ordm;C is referred to as cryoprecipitation. Two types of cryoprecipitates are recognized. Cryoglobulin (CG) is present when proteins precipitate from an individual's serum and plasma, and cryofibrinogen refers to the precipitate from plasma only [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cryoglobulins are either immunoglobulins or a mixture of immunoglobulins and complement components. The nature of cryoglobulins, an overview of the clinical syndromes associated with them (cryoglobulinemia, cryoglobulinemic vasculitis), their pathogenesis, associated disorders, and prognosis are the subjects of this topic review. Treatment of cryoglobulinemia due to plasma cell disorders (monoclonal CG) and the clinical manifestations, diagnosis, and treatment of the mixed cryoglobulinemic syndromes, such as those associated with hepatitis C infection, are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37626?source=see_link\">",
"     \"Treatment and prognosis of Waldenstr&ouml;m macroglobulinemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34040?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/52/36682?source=see_link\">",
"     \"Treatment of the mixed cryoglobulinemia syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As noted above, a precipitate that develops in refrigerated plasma (cryofibrinogen) is typically composed of a mixture of fibrinogen, fibrin, fibronectin, and fibrin split products. The clinical manifestations of cryofibrinogenemia and disorders associated with the presence of circulating cryofibrinogen are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7576?source=see_link\">",
"     \"Cryofibrinogenemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CRYOGLOBULIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryoglobulin (CG) consists of immunoglobulins and complement components and precipitates upon refrigeration of serum and plasma. Routine laboratory testing for cryoglobulin is, however, typically performed only on serum. The first description of the cryoprecipitation phenomenon has been attributed to Wintrobe and Buell, who described in 1933 a patient with signs and symptoms of hyperviscosity associated with multiple myeloma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/2\">",
"     2",
"    </a>",
"    ]. In 1947, the term &ldquo;cryoglobulin&rdquo; was applied to this &ldquo;cold precipitable serum globulin&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/3\">",
"     3",
"    </a>",
"    ]. The appearance of precipitated cryoglobulins is illustrated in the picture (",
"    <a class=\"graphic graphic_picture graphicRef82774 \" href=\"UTD.htm?33/11/33970\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CRYOGLOBULINEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although, strictly speaking, cryoglobulinemia refers to the presence of CG in a patient's serum, this term is often used to refer to a systemic inflammatory syndrome that generally involves small-to-medium vessel vasculitis due to CG-containing immune complexes. The terms &ldquo;cryoglobulinemic syndrome&rdquo; and &ldquo;cryoglobulinemic vasculitis&rdquo; are sometimes used to make a distinction between the clinically apparent disorder and the asymptomatic presence of cryoglobulins [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While the phenomenon of cryoprecipitation and associated hyperviscosity was described in the 1930s, the association of CG with the triad of palpable purpura, arthralgia, and myalgia was not described until the 1960s [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. It is important to note that these two different, yet highly representative, clinical syndromes generally reflect different types of underlying CG:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperviscosity is typically associated with CG due to hematological malignancies and monoclonal immunoglobulins.",
"     </li>",
"     <li>",
"      &ldquo;Meltzer's triad&rdquo; of palpable purpura, arthralgia, and myalgia is generally seen with polyclonal CGs seen in essential-, viral-, or connective tissue disease-associated CG.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of clinically-significant cryoglobulinemia has been estimated at approximately 1 in 100,000, although detectable levels of circulating CGs have been seen in a significant proportion of patients with chronic infections",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inflammation: 15 to 20 percent in HIV infection, 15 to 25 percent in connective tissue diseases, 40 to 65 percent in hepatitis C infected individuals, and as high as 64 percent in HIV and hepatitis C coinfection, perhaps especially among patients with hepatitis C genotype 1 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/9-13\">",
"     9-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, once the presence of CG has been demonstrated, further characterization of the CG may be helpful for diagnostic and prognostic purposes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An approach to the classification of the major forms of cryoglobulinemia is described below. Preliminary classification criteria, which require further validation, have been proposed for cryoglobulinemic vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Analysis of cryoglobulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;In order to analyze the nature of the CG, it must be redissolved by warming and then must be subjected to laboratory testing to determine its immunoglobulin and complement components. This is accomplished by performing immunodiffusion of the redissolved CG against antibodies directed to various immunoglobulin (Ig) heavy chains (IgG, IgM, etc) and light chains (eg, kappa and lambda) and to complement components (eg, C1q, C4, and C3) or similar immunological analyses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/58/10154?source=see_link\">",
"     \"Recognition of monoclonal proteins\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Brouet classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;One frequently used classification scheme is that of Brouet, which uses the immunological analysis of the CG to delineate the clonality of the responsible CG, particularly with regard to rheumatoid factor (RF) binding activity (",
"    <a class=\"graphic graphic_table graphicRef51371 \" href=\"UTD.htm?36/11/37052\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Type I",
"      </strong>",
"      &mdash; The presence of isolated monoclonal Ig (typically IgG or IgM, less commonly IgA or free immunoglobulin light chains) is the criterion for classification as a type I CG. The proportion of patients with a type I CG varies substantially among case series but accounts for about 5 to 25 percent of cases. The hematologic diagnoses are typically Waldenstr&ouml;m's macroglobulinemia or multiple myeloma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/47/762?source=see_link\">",
"       \"Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=see_link\">",
"       \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Type II",
"      </strong>",
"      &mdash; A mixture of polyclonal Ig in association with a monoclonal Ig, typically IgM or IgA, with rheumatoid factor activity defines type II CG. This type of CG, also called essential mixed cryoglobulinemia, accounts for approximately 40 to 60 percent of cases. Type II CGs are often due to persistent viral infections, particularly hepatitic C and human immunodeficiency virus infections. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34040?source=see_link\">",
"       \"Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Type III",
"      </strong>",
"      &mdash; Mixed cryoglobulins consisting of polyclonal immunoglobulins characterize type III CGs. Approximately 40 to 50 percent of all CG cases are type III, and these are often secondary to connective tissue diseases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While generally useful, this schema does not account for CGs that possess atypical characteristics, such as oligoclonal IgM components with or without trace polyclonal immunoglobulin responses, often referred to as type II-III [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/16,17\">",
"     16,17",
"    </a>",
"    ], or biclonal CGs [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Many speculate that such phenomena reflect an intermediate stage of transition between II and III, akin to the malignant transformation of gammopathies of unknown significance (eg, MGUS) to multiple myeloma or other lymphoproliferative disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/20\">",
"     20",
"    </a>",
"    ], but a direct pathogenic link has not been clearly demonstrated.",
"   </p>",
"   <p>",
"    Otherwise, CG syndromes are often classified as essential or secondary, based upon the presence of underlying diseases, particularly chronic hepatitis C virus (HCV) infection or connective tissue diseases (",
"    <a class=\"graphic graphic_table graphicRef77121 graphicRef52034 \" href=\"UTD.htm?17/33/17950\">",
"     table 2A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/21\">",
"     21",
"    </a>",
"    ]. At the same time, the clinical features of both essential and secondary CG overlap somewhat, with respect to Brouet subtype and organ involvement, making most distinctions among CG syndromes somewhat difficult to interpret consistently.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since minute levels of CG are often detectable in the serum of healthy persons, many researchers have speculated that they reflect the ongoing physiological clearance of endogenous immune complexes by immunoglobulins with rheumatoid factor activity [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/15,22\">",
"     15,22",
"    </a>",
"    ]. In such a scenario, pathogenic CG responses would result from several factors, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Chronic immune stimulation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lymphoproliferation, resulting in the production of higher concentrations of mono-, oligo-, or polyclonal CG",
"     </li>",
"     <li>",
"      Immune complex formation among CGs",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      their target antigens",
"     </li>",
"     <li>",
"      Defective",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      insufficient clearance of the resulting immune complexes, which accumulate and mediate disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    CG pathogenesis may depend upon a poorly understood interaction between a polygenic host predisposition and environmental triggers, but specifically responsible genes remain unidentified. Major histocompatibility complex associations, for instance, have been extensively investigated, but with inconsistent findings [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/23\">",
"     23",
"    </a>",
"    ]. In HCV-associated mixed cryoglobulinemia, particularly significantly elevated levels of inflammatory cytokines, such as IL-1beta, IL-6, and TNF-alpha, have been observed, suggesting a particular role for CG-induced inflammation in disease pathogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although human immunodeficiency virus (HIV) and hepatic C virus coinfection are relatively common, the combination of the two viral agents appears to have little or no effect upon the prevalence of CG or symptomatic CG syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/25\">",
"     25",
"    </a>",
"    ]. Other infectious agents proposed, but not proven, to have an association with cryoglobulinemia include hepatitis B, cytomegalovirus, Epstein-Barr virus, and human parvovirus B19 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Type I CG",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prototypical paradigm of CG pathogenesis, type I cryoglobulinemia, causes hyperviscosity that results from high levels of monoclonal cryoglobulin due to an underlying lymphoproliferative disorder. These immunoglobulins form cold-induced precipitates. In vivo, such aggregates may physically obstruct vessels",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mediate inflammatory vasculitis via immune complex deposition (see",
"    <a class=\"local\" href=\"#H24\">",
"     'Pathological findings'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/27\">",
"     27",
"    </a>",
"    ], as suggested by studies of human cryoglobulins in animal models [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/28\">",
"     28",
"    </a>",
"    ]. Nevertheless, for many CGs, aggregation and pathogenicity appear to depend also upon antibody-specific conditions of temperature, pH, CG concentration, and weak noncovalent factors [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Types II and III CG",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mixed CGs (types II and III) generally result from chronic inflammatory states, such as connective tissue diseases, like systemic lupus erythematosus or Sj&ouml;gren's syndrome, or viral infections, such as HCV, although lymphoproliferative disorders have rarely been associated as well. Many of these disease states share B cell hyperactivation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hyperproliferation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/13,30\">",
"     13,30",
"    </a>",
"    ], which seem to predispose to the selective expansion of CG-producing B cell clone(s) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/31\">",
"     31",
"    </a>",
"    ], but a precise ontology of pathogenic CGs in mixed CG has not been delineated. This paradigm of pathogenesis has been most intensively studied for chronic HCV infection, in which B cell hyperactivation may result upon direct infection via the cell surface protein CD81 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/32\">",
"     32",
"    </a>",
"    ], via chronic, antigen-nonspecific stimulation by macromolecular serum complexes containing HCV, including HCV-IgG and HCV-lipoprotein [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/33,34\">",
"     33,34",
"    </a>",
"    ], or via an HCV antigen-specific mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/35\">",
"     35",
"    </a>",
"    ], resulting in expansion of specific B cell clones such as those expressing the WA idiotype [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/36\">",
"     36",
"    </a>",
"    ] or V(H)1-69 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/37\">",
"     37",
"    </a>",
"    ]. HCV particles are often found in such patients' serum CG complexes, but, at the same time, CG development in hepatitis C infection does not directly require the HCV virion or its components [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/38\">",
"     38",
"    </a>",
"    ]. In this sense, CG development may, in fact, reflect a normal, expected response to regulate immune complexes in states of chronic immune activation.",
"   </p>",
"   <p>",
"    Among patients with HCV infection, the number of circulating T cells with surface markers compatible with a suppressor phenotype may be a feature that differs between patients with cryoglobulinemic vasculitis and those with asymptomatic CG. This was illustrated in a study that compared the percentage of &ldquo;regulatory&rdquo; T cells in 69 patients with HCV infection who had symptomatic CG with others with asymptomatic HCV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/39\">",
"     39",
"    </a>",
"    ]. The mean levels of regulatory T cells were significantly lower in those with symptomatic HCV-associated CG than asymptomatic subjects (2.6 versus 7.4 percent, respectively). Whether the diminished proportion of regulatory T cells plays a role in causing vasculitis is uncertain but warrants further exploration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Aggregation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The molecular characteristics of CG similarly vary, depending upon the underlying disease state. Most commonly, CGs consist of germline autoantibodies with rheumatoid factor activity, suggesting an antigen-independent, hyperproliferative etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/33,40\">",
"     33,40",
"    </a>",
"    ]. Nevertheless, non-rheumatoid factor CGs have been described, mostly in type I responses, in which cryoprecipitability seems to be mediated by other characteristics of the Ig molecule itself, such as the absence of sialic acid moieties [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/41\">",
"     41",
"    </a>",
"    ]. Furthermore, specific factors may be required within the IgG",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    target antigen(s) of the CG, especially in the mixed cryoglobulinemias, since many cryoprecipitates best form between the CG in association with the respective patient's IgG",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    its Fc, not with IgG from normal serum [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/42\">",
"     42",
"    </a>",
"    ]. These findings suggest that CGs result from the specific selection of antibodies with such characteristics by the pathological processes responsible for CG development, rather than emerging from a random, stochastic process.",
"   </p>",
"   <p>",
"    Classically, the overproduction of CG and the resulting aggregates",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    immune complexes are thought to overwhelm normal reticuloendothelial activity, perhaps by impairing normal Fc receptor function, leading to the accumulation of serum CG complexes which induce disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Indeed, some familial forms of CG have been associated with deficiencies in complement proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/45,46\">",
"     45,46",
"    </a>",
"    ] and presumably result from the inability of these patients to effectively clear CG-containing immune complexes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical presentations of CG syndromes vary substantially among some series, probably due in large part to both differences of case definition and prevalence of secondary etiologies (",
"    <a class=\"graphic graphic_table graphicRef51371 \" href=\"UTD.htm?36/11/37052\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/47\">",
"     47",
"    </a>",
"    ]. Most investigators agree that the majority of people with CG are asymptomatic. When a clinically significant disorder is associated with the presence of CGs, the symptoms and physical findings are generally correlated with the underlying Brouet type of CG.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Type I CG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with detectable type I GC are asymptomatic. Type I CG classically produces signs related to hyperviscosity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thrombosis: Raynaud phenomenon, digital ischemia, livedo reticularis, and purpura may occur. In severe cases, without treatment, this may progress to gangrene.",
"   </p>",
"   <p>",
"    Neurologic symptoms due to hyperviscosity include blurring or loss of vision, headache, vertigo, nystagmus, dizziness, sudden deafness, diplopia, ataxia, confusion, dementia, disturbances of consciousness, stroke, or coma. The epidemiology and prognosis of type I CG has largely reflected the usually underlying lymphoproliferative disorder, such as Waldenstr&ouml;m's macroglobulinemia or multiple myeloma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/47/762?source=see_link&amp;anchor=H7#H7\">",
"     \"Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia\", section on 'Hyperviscosity syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=see_link\">",
"     \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Mixed CGs (Types II and III)",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast, mixed CGs most often produce constitutional and nonspecific symptoms, such as arthralgias, fatigue, and myalgias, as well as palpable purpura due to cutaneous vasculitis and sensory changes or weakness due to peripheral neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/48\">",
"     48",
"    </a>",
"    ]. Nevertheless, the classical \"Meltzer's triad\" of purpura, arthralgias, and weakness is seen in as few as 25 to 30 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/7,21\">",
"     7,21",
"    </a>",
"    ]. Female-to-male ratio is often reported as 1.3 to 1.5:1, with average age of onset in the sixth decade and time to diagnosis varying from 0 to 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/49\">",
"     49",
"    </a>",
"    ]. Manifestations often wax and wane over time, with spontaneous remissions and exacerbations [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/5\">",
"     5",
"    </a>",
"    ]. Symptoms often last one to two weeks, recurring one to two times per month, but, in severe cases, discrete exacerbations may be difficult to discern.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Cutaneous",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous manifestations develop in nearly all patients with CG syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/15,21,50,51\">",
"     15,21,50,51",
"    </a>",
"    ] and may precede extracutaneous manifestations by decades. Typically, these lesions consist of erythematous macules to purpuric papules of the lower extremities (90 to 95 percent) (",
"    <a class=\"graphic graphic_picture graphicRef51770 \" href=\"UTD.htm?19/0/19461\">",
"     picture 2",
"    </a>",
"    ), though infarction, hemorrhagic crusts, and ulcers also occur (10 to 25 percent), generally in patients with type I CG. Similarly, Raynaud phenomenon, livedo reticularis, and acrocyanosis more commonly manifest in type I CG. Lesions sometimes appear on the head, neck, and mucosal surfaces, but again this distribution is more commonly seen in type I CG. Post-inflammatory hyperpigmentation (30 to 50 percent) and exacerbation as a result of cold exposure (10 to 30 percent) are common. Morphological abnormalities of the nailfold vasculature, including tortuosity and apical enlargement, are typical at capillaroscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Musculoskeletal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Musculoskeletal complaints such as arthralgias and myalgias are common in the mixed CGs, but frank arthritis or myositis is rare to uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/23,53\">",
"     23,53",
"    </a>",
"    ]. Arthralgias are typically described in over 70 percent of patients, especially affecting the metacarpophalangeal, proximal phalangeal, knees, and ankles, often in type III CG and often exacerbated by cold exposure. Many suggest that such complaints typically accompany CG syndromes in association with connective tissue diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/21\">",
"     21",
"    </a>",
"    ]. They rarely accompany type I CG.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuropathy affects a high percentage of mixed, in contrast to type I, CG patients, but clinically significant neuropathy is uncommon. Electromyographic and nerve conduction studies have demonstrated the presence of peripheral neuropathy, presumably due to vasculitis, in over 70 to 80 percent of patients with mixed CG [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/22,54,55\">",
"     22,54,55",
"    </a>",
"    ], but many symptom-based demographic studies report prevalences of only 5 to 45 percent. These manifestations may be more prevalent in non-liver disease-associated CG syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/21\">",
"     21",
"    </a>",
"    ]. Severe peripheral neuropathy, such as mononeuropathy multiplex or combined sensorimotor disease, remains uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22423?source=see_link\">",
"     \"Clinical manifestations of vasculitic neuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Pulmonary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subclinical pulmonary manifestations appear to be common in mixed, but not type I, CG [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/59-61\">",
"     59-61",
"    </a>",
"    ]. Pulmonary function tests often reveal evidence of small airways disease and impairment of gas exchange, with symptoms in approximately 40 to 50 percent of patients, usually ranging from dyspnea to cough and pleurisy. Bronchiolitis obliterans organizing pneumonia (BOOP), pulmonary hemorrhage, and pulmonary vasculitis have been reported but appear to be very uncommon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Renal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal disease in mixed CG often results from immune complex disease or, less often, as a result of thrombotic disease (the latter more often seen in type I disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/15,62\">",
"     15,62",
"    </a>",
"    ]. Cryoglobulinemia was the cause of biopsy proven glomerulonephritis in approximately 2 percent of cases in an Italian registry of renal biopsies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Membranoproliferative glomerulonephritis seems to be more common in mixed CG, and variations in underlying etiology likely account for the wide variation in incidences of renal disease among various case series (5 to 60 percent). Isolated proteinuria or hematuria occurs much more frequently than nephrotic or nephritic syndromes or acute renal failure. Most patients declare a chronic or rapidly progressive disease course within three to five years of diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34040?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other organ systems may be involved in CG syndromes but have been predominantly described in mixed CG states, and their pathophysiology remains somewhat obscure. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sj&ouml;gren's syndrome has been reported in 4 to 20 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/21,59\">",
"       21,59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Raynaud phenomenon has been reported in as many as half of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/21,59,64\">",
"       21,59,64",
"      </a>",
"      ], generally in association with diseases like systemic lupus erythematosus or rheumatoid arthritis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other manifestations have been reported with varying frequency, such as hepatomegaly, abnormal liver function tests, or abnormal liver biopsy in up to 90 percent; lymphadenopathy in up to 20 percent; splenomegaly in up to 30 percent; and abdominal pain in up to 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/22,64\">",
"     22,64",
"    </a>",
"    ]. For each, various pathologies have been speculated upon but not fully explored; for example, many consider hepatomegaly to represent evidence of chronic hepatitis or other liver disease or consider abdominal pain to reflect active mesenteric vasculitis. Clinically significant vasculitis of most other internal organs, such as of the heart, central nervous system, and retinal vessels, rarely complicates any of the cryoglobulinemic syndromes with the possible exception of those with hyperviscosity due to type I CG. However, pathologic findings (see below) suggest that more widespread, though subclinical, involvement may be more frequent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     PATHOLOGICAL FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type I CG (monoclonal Ig containing) predominantly affects the skin, kidney, and bone marrow, and mixed CG (types II and III) predominantly involves the skin, peripheral nervous system, and kidney. Autopsy studies of mixed CG have revealed extensive, yet often clinically inapparent, vasculitis of the heart, gastrointestinal tract, central nervous system, muscles, lung, liver, and adrenals [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/50\">",
"     50",
"    </a>",
"    ]. A common feature at involved sites in skin, muscle, lung, and kidney is the presence of eosinophilic material within the lumen of small vessels; these deposits often extend into the intimal region and are associated with inflammation of the vessel wall [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/65\">",
"     65",
"    </a>",
"    ]. These deposits may also stain with periodic acid Schiff (PAS) stain as illustrated in a glomerular capillary (",
"    <a class=\"graphic graphic_picture graphicRef71702 \" href=\"UTD.htm?28/57/29593\">",
"     picture 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Cutaneous",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin lesions in mixed CG most often reveal leukocytoclastic vasculitis (50 percent), less commonly inflammatory or noninflammatory purpura (10 to 20 percent) (",
"    <a class=\"graphic graphic_picture graphicRef54126 \" href=\"UTD.htm?4/43/4793\">",
"     picture 4",
"    </a>",
"    ), noninflammatory hyaline thrombosis (10 percent), or post-inflammatory sequelae (10 percent). Direct immunofluorescence microscopy of acute lesions often reveals deposits of IgM, IgG,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    C3 complement.",
"   </p>",
"   <p>",
"    In contrast, type I CGs more often induce noninflammatory thrombotic lesions, sometimes with evidence of cutaneous infarction or hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/15,50,66\">",
"     15,50,66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Peripheral nerve",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral nerve lesions typically demonstrate vasculitis, generally of the epineural vessels, in mixed CG [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/56,67-71\">",
"     56,67-71",
"    </a>",
"    ]. Necrotizing vasculitis or demyelination may be present, with occasional deposits of immunoglobulin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    complement. Pauciinflammatory occlusive lesions are sometimes seen as well, suggesting a primary role for neuronal ischemia in disease pathogenesis, and are more suggestive of type I CG. Affected nerves often display axonal degeneration, likely secondary to disease of the vasa vasorum. Most studies have focused upon histopathology of sural nerve biopsies, which are presumed to reflect systemic neuronal damage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Renal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal disease in mixed CG is presumed to reflect immune complex-mediated inflammatory damage, with or without ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/50,72\">",
"     50,72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Light and immunofluorescence microscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most commonly encountered is membranoproliferative glomerulonephritis (60 to 80 percent), with endocapillary proliferation and subendothelial",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intraluminal deposits of CGs, immunoglobulin,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    complement proteins (",
"    <a class=\"graphic graphic_picture graphicRef71702 \" href=\"UTD.htm?28/57/29593\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef60046 \" href=\"UTD.htm?39/26/40367\">",
"     picture 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/73\">",
"     73",
"    </a>",
"    ]. Less commonly seen, but not mutually exclusive, are mesangial proliferative glomerulonephropathy, intraglomerular hyaline thrombi, and vasculitis with fibrinoid necrosis (about 20 percent, 25 percent, and 30 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/22,74,75\">",
"     22,74,75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Type I CG generally produces noninflammatory glomerulopathies, including thrombotic and hypocellular lesions, without evidence of vasculitis. However, type I CG may rarely produce frank glomerulonephritis, as was documented in two cases of membranoproliferative disease, both involving IgG monoclonal CGs of the same isotype [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Electron microscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;When renal biopsy specimens are examined with electron microscopy, amorphous or granular dense subendothelial deposits may be present (",
"    <a class=\"graphic graphic_picture graphicRef69200 \" href=\"UTD.htm?22/59/23481\">",
"     picture 6",
"    </a>",
"    ). The presence of electron-dense deposits that have a \"fingerprint\"-like appearance (",
"    <a class=\"graphic graphic_picture graphicRef81450 \" href=\"UTD.htm?35/5/35929\">",
"     picture 7",
"    </a>",
"    ) may provide a clue to the presence of cryoglobulins [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/77\">",
"     77",
"    </a>",
"    ]. However, similar structures have been noted in other types of renal disease, particularly lupus nephritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Bone marrow",
"    </span>",
"    &nbsp;&mdash;&nbsp;In type I CG, bone marrow examination often reveals evidence of an underlying hematological condition, such as plasma cell malignancy in multiple myeloma. Few studies have systematically explored bone marrow findings in mixed CG, but monomorphic clusters of small lymphocytes, often with plasmacytoid features and associated with overexpression of the Bcl-2 protooncogene, have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/78,79\">",
"     78,79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     LABORATORY FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overall, the presence of a measurable amount of CG (cryocrit) remains the most prominent laboratory hallmark of CG syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/50\">",
"     50",
"    </a>",
"    ]. Several other serological findings have often been reported, but none are pathognomonic, since they often are encountered in normal individuals",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other confounding medical conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Cryoglobulins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 40 percent of normal individuals possess detectable CG, typically in concentrations of less than 80",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/15,22\">",
"     15,22",
"    </a>",
"    ], but these small quantities are generally insufficient to generate a detectable cryocrit. As a result, the vast majority of healthy individuals will have negative results upon testing for CG. In contrast, mixed CGs of both types II and III generally produce higher concentrations of 1 to 5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.01 to 0.05",
"    <span class=\"nowrap\">",
"     g/L),",
"    </span>",
"    although some studies suggest that type III levels typically remain less than 1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.01",
"    <span class=\"nowrap\">",
"     g/L).",
"    </span>",
"    By contrast, many type I CGs are present in concentrations greater than 5 or 10",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.05 or 0.1",
"    <span class=\"nowrap\">",
"     g/L)",
"    </span>",
"    with cryocrits over 70 percent.",
"   </p>",
"   <p>",
"    Particularly in high CG titer states, cryoprecipitates during blood collection often produce cloud-like structures on peripheral blood smears and may be mistaken for leukocytes or platelets by automated cell differential analyzers [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/80\">",
"     80",
"    </a>",
"    ] or for producing pseudoleukocytosis or pseudothrombocytosis as reported by automated cell counters [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/81,82\">",
"     81,82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Complement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diminished serum complement components may reflect ongoing consumption by CG-containing or CG-propagated immune complexes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/21,83\">",
"     21,83",
"    </a>",
"    ]. Type I CG typically produces few serological complement abnormalities, but mixed CG sera often demonstrate reduced levels of total hemolytic complement (CH50) and early complement proteins C1q, C2, and C4, particularly in type II CG as well as in type III CG associated with collagen-vascular disease. Levels of C3 are generally unaffected or only mildly diminished. Late complement components are also usually insignificantly affected, although modest elevations have been reported. Abnormalities of early complement proteins also occur in many other medical conditions, including systemic lupus erythematosus or some infections [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Acute phase reactants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other tests appear to reflect a chronic inflammatory response. Those sensitive to acute phase reactants such as the erythrocyte sedimentation rate (ESR) and C-reactive protein concentration are generally elevated, and the ESR can be strikingly so in type I CG, reflective of the underlying monoclonal immunoglobulin. Mild to moderate hypergammaglobulinemia of IgM, IgA,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    IgG also typifies mixed CG, with extreme, often monoclonal, levels more indicative of type I disease. Rarely, hypogammaglobulinemia, particularly of IgG, is seen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Autoantibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoantibodies, such as antinuclear antibodies and RF, are often present in the serum of patients with mixed cryoglobulins [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/21,47\">",
"     21,47",
"    </a>",
"    ]; these include smooth muscle, parietal cell, thyroglobulin, microsomal, U1 ribonucleoprotein, Sm, Ro, La, mitochondrial, phospholipid, and neutrophil cytoplasmic specificities, perhaps reflecting the large overlap of CG with many connective tissue diseases and other autoimmune syndromes. Blood viscosity is mildly increased [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/85\">",
"     85",
"    </a>",
"    ], and a mild normochromic, normocytic anemia is often detectable. False positive test results for antibodies to citrulline-containing antigens in a small proportion of patients with hepatitis C related CG (7 percent) have been ascribed to nonspecific binding of immunoglobulins in the assay [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Evidence of viral infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serological studies, particularly for viral hepatitis, are generally indicated during the laboratory evaluation of a patient with mixed CG, but the overall prevalence of positive results among patients with CG varies substantially among study groups. For instance, hepatitis C has been reported in up to 98 percent of patients with CG syndromes, but other populations may have substantially lower rates [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/33,87\">",
"     33,87",
"    </a>",
"    ]. Similarly, serological studies for other agents, including hepatitis B, HIV, and Epstein-Barr virus, have been somewhat inconsistent but are generally worth at least considering during the work-up of CG [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/88,89\">",
"     88,89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of CG syndromes rests principally in the laboratory demonstration of serum cryoglobulins in association with characteristic clinical signs and symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34040?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Detection and analysis of cryoglobulins",
"    </span>",
"    &nbsp;&mdash;&nbsp;To detect CG, 10 to 20 mL of blood are drawn into syringes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    collection tubes that have been",
"    <strong>",
"     prewarmed to 37&ordm;C without anticoagulants",
"    </strong>",
"    . These precautions are required because failure to prewarm may lead to false-negative results, due to loss of the cryoglobulin in the clotted blood (eg, if there is cooling below 37&ordm;C during collection, clotting, or centrifugation), and because the presence of anticoagulants may produce false-positive results due to the formation of cryofibrinogen or heparin-precipitable complexes.",
"   </p>",
"   <p>",
"    After clotting at 37&ordm;C for one-half to one hour, the serum is separated by centrifugation at 37&ordm;C, is placed in a graduated (Wintrobe) tube, and is refrigerated (4&ordm;C) to allow the precipitation of CG. In type I CG, precipitates are often seen within 24 hours (sometimes in less than 90 minutes). However, three to five days are usually allowed for complete precipitation, especially for the mixed CGs, and some type II and type III cryoglobulins require up to seven days for precipitation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/90\">",
"     90",
"    </a>",
"    ]. Most laboratories will determine a cryocrit, which is a measure of the packed (centrifuged) volume of the precipitate as a percentage of the original serum volume at 4&ordm;C.",
"   </p>",
"   <p>",
"    Further confidence in the cryocrit as reflecting true CG is obtained by washing the precipitate three to six times in cold saline solution to reduce the possibility of precipitated salts or other proteins. In addition, the precipitate can then be redissolved in saline at 37&ordm;C to confirm the warm solubility of the CGs. At this time, CG protein concentration can be determined by spectrophotometry. Further characterization can be accomplished by immunofixation, enzyme linked immunosorbent assay (ELISA), or another specific immunological assay.",
"   </p>",
"   <p>",
"    Some laboratories perform further testing consisting of a measurement of absolute CG concentration, along with a description of the components of the immune complexes, including mono- or polyclonality of IgM, IgG, IgA, IgE, kappa,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lambda light chains. In type II cryoglobulinemia, the monoclonal component is typically IgM kappa with rheumatoid factor activity. Many laboratories, however, report only the cryocrit.",
"   </p>",
"   <p>",
"    The cryocrit in individuals without cryoglobulinemia is close to zero; generally a cryocrit over 0.5 to 1 percent or cryoglobulin concentration over 20 to 50",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    is considered clinically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/50,91,92\">",
"     50,91,92",
"    </a>",
"    ]. The cryocrit in affected patients may approach 50 percent or may encompass the entire serum volume in type I cryoglobulinemia. The cryocrit is generally between 2 and 7 percent in type II and between 1 and 3 percent in type III disease, but there is a poor correlation between the cryocrit and clinical symptoms and features. For example, only a small proportion of patients with chronic HCV and type II or III CG have the mixed cryoglobulinemia syndrome with vasculitis or purpura, while, in some patients with the syndrome, CG may be difficult to detect. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34040?source=see_link&amp;anchor=H64200389#H64200389\">",
"     \"Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)\", section on 'Testing for cryoglobulins'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When cryoglobulinemia is suspected clinically, a negative result from routine laboratory testing for CGs does not exclude CG-mediated disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/93\">",
"     93",
"    </a>",
"    ]. The clinician may need to draw a new specimen after consulting with the laboratory staff or clinical pathologist to assure that procedures are in place for the appropriate handling of the patient's blood when the sample is obtained and transported and to be certain that the laboratory has the necessary equipment (particularly a temperature controlled centrifuge) to prevent premature cooling of the sample.",
"   </p>",
"   <p>",
"    There is no international standard for the detection, analysis, and reporting of cryoglobulins [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/94\">",
"     94",
"    </a>",
"    ]. Since many healthy individuals have detectable amounts of cryoglobulins, a so-called normal range for the total protein content in the cryoprecipitate has been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/95\">",
"     95",
"    </a>",
"    ]. However, only a few laboratories provide cryoprecipitate-specific reference values for total protein content [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/90\">",
"     90",
"    </a>",
"    ]. An additional problem is that protein content and cryocrit are only indirect measures of cryocrit concentration since its quantification is affected by the presence of other serum proteins, such as albumin and immunoglobulins [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While candidate antigens have been detected in the cryoprecipitate (eg, hepatitis B or C), these viral proteins are typically present in serum as well. Assaying the CG for such antigens is seldom, if ever, clinically indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Syndromic diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosis of a clinical disorder in association with CG requires a careful consideration of combined clinical, laboratory, and pathological data. Few investigators have adhered to any of the several proposed classification criteria for the CG syndrome. While there is no consensus, the following are criteria that seem generally acceptable:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Demonstration of a persistently elevated cryocrit, such as greater than 1 percent for three to six months [",
"      <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/97\">",
"       97",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Plus one or more of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical indicators of cryoglobulinemic vasculitis or thrombosis, such as lower extremity purpura, particularly with evidence of leukocytoclastic vasculitis on biopsy or diminished serum C4 concentration",
"     </li>",
"     <li>",
"      Direct evidence of cryoglobulins from pathological thrombotic or vasculitic specimens, such as by elution and cryoprecipitation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      immunofixation. While this direct demonstration of CG may provide the most definitive evidence, it is rarely sought in clinical practice, which is consistent with the classification criteria for cryoglobulinemic vasculitis proposed by the Italian Study Group on Cryoglobulinemia [",
"      <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/14\">",
"       14",
"      </a>",
"      ]. Still, in the absence of firm evidence, the clinician is often left with nonspecific symptoms, such as weakness or arthralgias, and the presence of serum CG upon which to make a diagnosis. Here, evidence of a frequently associated disorder, such as HCV infection or a clinically evident systemic disease (eg Sj&ouml;gren's syndrome) may make the diagnosis more secure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Differential diagnosis (DDX)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of cryoglobulinemia varies depending upon the clinical presentation. The following discussion deals with the most frequent scenarios.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h3\">",
"     DDX: Cryoglobulinemic vasculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of cryoglobulinemic vasculitis includes other vasculitides that affect small or medium-sized vessels; these include drug-induced small vessel vasculitis (hypersensitivity vasculitis), Henoch-Sch&ouml;nlein purpura (IgA vasculitis), ANCA-associated vasculitis (eg, granulomatosis with polyangiitis [Wegener&rsquo;s], microscopic polyangiitis, Churg Strauss syndrome), infection related vasculitis (eg, bacterial endocarditis, poststreptococcal vasculitis and glomerulonephritis), and vasculitis associated with a connective tissue disorder (eg, systemic lupus erythematosus, rheumatoid arthritis, Sj&ouml;gren's syndrome). In addition, disorders that mimic the symptoms and findings of vasculitis, including infectious (eg, Rickettsial infections, malaria, Babesiosis), thrombotic, and embolic disorders (eg, antiphospholipid syndrome, thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, atrial myxoma), may warrant consideration. The differential diagnosis of vasculitis is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=see_link&amp;anchor=H42#H42\">",
"     \"Classification of and approach to the vasculitides in adults\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h3\">",
"     DDX: Cryoglobulinemic hyperviscosity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Slow flow and impaired tissue perfusion affecting many organs may be due to marked elevation of the cellular contents of the blood (eg, leukostasis, polycythemia), partial obstruction by sickled red blood cells, parasitized cells (eg, malaria, Babesiosis), or increased viscosity due to polyclonal or monoclonal immunoglobulins that are not cryoglobulins (eg, Waldenstr&ouml;m&rsquo;s hyperglobulinemic purpura and Waldenstrom macroglobulinemia).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of CG per se does not seem to confer a significant morbidity or mortality risk over and above the underlying conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mean survival is approximately 70 percent at 10 years after the onset of symptoms and 50 percent at 10 years after diagnosis, with death typically resulting from infection and cardiovascular disease. Liver failure remains a large concern, but the historical correlation likely relates to the underlying activity of chronic hepatitis C infection, which often coexists in CG patients. The prognosis for such patients depends upon their response to treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/52/36682?source=see_link\">",
"     \"Treatment of the mixed cryoglobulinemia syndrome\"",
"    </a>",
"    .) Some complications of CG predict poorer outcomes, including renal failure and development of a lymphoproliferative or plasma cell disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     Renal failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of development of renal failure may be greater in those with hepatitis C associated disease than in those with idiopathic (essential) mixed cryoglobulinemia. This was illustrated in one study of 17 patients, 11 of whom had hepatitis C infection; 5 of 11 of these patients developed renal failure, while none of the 6 patients free of infection had progressive renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/73\">",
"     73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37353?source=see_link\">",
"     \"Renal disease associated with hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     Lymphoproliferative disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary lymphoproliferative disorders sometimes occur, generally manifesting in type II patients 5 to 10 years after diagnosis, but do so in less than 5 to 10 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/98-100\">",
"     98-100",
"    </a>",
"    ]. The malignancy is often a B cell non-Hodgkin lymphoma, approximately 50 percent intermediate-to-high grade lymphoma and approximately 50 percent low-grade tumors such as immunocytoma (70 to 80 percent), mucosa-associated lymphoid tumors, or centrocytic follicular lymphoma.",
"   </p>",
"   <p>",
"    Among patients with hepatitis C associated type II cryoglobulinemia, the incidence of non-Hodgkin lymphoma is estimated to be 35-fold higher than in the general population. The distribution of aggressive and nonaggressive histologic types is similar to that noted above for unselected patients with cryoglobulinemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15498?source=see_link&amp;anchor=H5#H5\">",
"     \"Extrahepatic manifestations of hepatitis C virus infection\", section on 'Lymphoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, prognosis generally relates to the underlying disease state(s) or developing complication(s), especially in type I CG where the patient often suffers from a primary lymphoproliferative disorder. Several studies have suggested that a handful of findings suggests poorer outcomes (ie, renal insufficiency, four or more extrarenal manifestations, hypertension, and infectious complications [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/15,50\">",
"     15,50",
"    </a>",
"    ]) but little is known about the relative contributions of each.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of cryoglobulinemia depends upon the underlying disorder and upon the severity and nature of involvement. In patients with mixed cryoglobulinemia, the treatment is directed at the underlying infectious or autoimmune disorder, as well as the vasculitis that may occur. In patients with monoclonal (type 1) CG associated with a lymphoproliferative disorder, the treatment is focused on the underlying malignancy and the risk or presence of complications such as hyperviscosity syndrome. Some patients with hyperviscosity may require treatment with plasma exchange. Treatment of cryoglobulinemia is discussed in detail elsewhere (see appropriate topic reviews). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/52/36682?source=see_link\">",
"     \"Treatment of the mixed cryoglobulinemia syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37626?source=see_link\">",
"     \"Treatment and prognosis of Waldenstr&ouml;m macroglobulinemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/12/12484?source=see_link\">",
"     \"Plasma exchange in the hyperviscosity syndrome due to immunoglobulins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several case reports have described the management of cryoglobulinemia in individual patients during pregnancy or in the neonate [",
"    <a class=\"abstract\" href=\"UTD.htm?21/63/22522/abstract/101-103\">",
"     101-103",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5780053\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryoglobulin (CG) consists of immunoglobulins (Ig) and complement components and precipitates upon refrigeration of serum. The term cryoglobulinemia is often used to refer to a systemic inflammatory syndrome that generally involves small to medium vessel vasculitis due to CG-containing immune complexes. Hyperviscosity is typically associated with CG due to hematological malignancies and monoclonal immunoglobulins, while \"Meltzer's triad\" of palpable purpura, arthralgia, and myalgia is generally seen with polyclonal CGs present in essential, viral, or systemic rheumatic disease-associated CG. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Cryoglobulin'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H3\">",
"     'Cryoglobulinemia'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Brouet classification uses the immunological analysis of the CG to delineate the clonality of the responsible CG, particularly with regard to rheumatoid factor (RF) binding activity (",
"      <a class=\"graphic graphic_table graphicRef51371 \" href=\"UTD.htm?36/11/37052\">",
"       table 1",
"      </a>",
"      ). Type I CG (5 to 25 percent of CG), in which an isolated monoclonal Ig (typically IgG or IgM) is present, is usually associated with a hematologic malignancy such as Waldenstr&ouml;m's macroglobulinemia or multiple myeloma. In type II CG (40 to 60 percent of CG), there is a mixture of polyclonal Ig in association with a monoclonal Ig, typically IgM or IgA, with RF activity. This type of CG, also called essential mixed cryoglobulinemia, is often due to persistent viral infections, particularly hepatitic C and human immunodeficiency virus infections. Mixed CG consisting of polyclonal Ig characterizes type III CGs (40 to 50 percent of CG), which are often secondary to systemic rheumatic diseases. CG syndromes are often classified as essential or secondary, based upon the presence of underlying diseases. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Classification'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Analysis of cryoglobulin'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Brouet classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Minute levels of CG are sometimes detectable in the serum of healthy persons, which may reflect the ongoing physiological clearance of endogenous immune complexes by Ig with RF activity. Pathogenic CG responses may result from factors, including chronic immune stimulation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lymphoproliferation, which result in the production of higher concentrations of mono-, oligo-, or polyclonal CG; immune complex formation among CG",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      their target antigens; and defective",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      insufficient clearance of the resulting immune complexes, which accumulate and mediate disease. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Aggregation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Etiology and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of people with CG are asymptomatic. The symptoms and physical findings are generally correlated with the underlying CG type when a clinically significant disorder is associated with the CGs. Cutaneous manifestations occur in most patients. Type I CG is often asymptomatic but also classically produces signs related to hyperviscosity",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      thrombosis, such as Raynaud phenomenon, digital ischemia, livedo reticularis, purpura, and neurologic symptoms.",
"      <strong>",
"      </strong>",
"      In contrast, mixed CGs most often produce constitutional and nonspecific symptoms, such as arthralgias, fatigue, and myalgias, as well as palpable purpura due to cutaneous vasculitis and sensory changes or weakness due to peripheral neuropathy. Pulmonary manifestations, often subclinical, may occur. Immune complex renal disease may occur in mixed CG; less often, thrombotic disease may occur in patients with type I CG. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Type I CG predominantly affects the skin, kidney, and bone marrow, and mixed CG (types II and III) predominantly involves the skin, peripheral nervous system, and kidney. Autopsy studies of mixed CG have revealed extensive, yet often clinically inapparent, vasculitis in additional sites. A common feature at involved sites in skin, muscle, lung, and kidney is the presence of eosinophilic material within the lumen of small vessels; these deposits often extend into the intimal region and are associated with inflammation of the vessel wall. Pathologic findings, such as leukocytoclastic vasculitis or immune-complex related injury, vary with the type of CG and the involved site. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Pathological findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presence of a measurable amount of CG (cryocrit) remains the most prominent laboratory hallmark of CG syndromes. Several other serological findings have often been reported, but none are pathognomonic, since they often are encountered in normal individuals",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      other confounding medical conditions. These include decreased levels of complement, elevated acute phase reactants, autoantibodies, and positive viral serologies. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Laboratory findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of CG syndromes rests principally in the laboratory demonstration of serum cryoglobulins in association with characteristic clinical signs and symptoms (eg, vasculitic syndromes versus disorders associated with hyperviscosity). (See",
"      <a class=\"local\" href=\"#H37\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H40\">",
"       'Differential diagnosis (DDX)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To detect CG, 10 to 20 mL of blood are drawn into syringes",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      collection tubes that have been prewarmed to 37&ordm;C without anticoagulants. After clotting at 37&ordm;C for one-half to one hour, the serum is separated by centrifugation at 37&ordm;C, is placed in a graduated (Wintrobe) tube, and is refrigerated (4&ordm;C) for three to five days to allow for complete precipitation of CG. A cryocrit is then determined by measuring the packed (centrifuged) volume of the precipitate as a percentage of the original serum volume at 4&ordm;C. (See",
"      <a class=\"local\" href=\"#H38\">",
"       'Detection and analysis of cryoglobulins'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presence of CG per se does not seem to confer a significant morbidity or mortality risk over and above the underlying conditions; prognosis generally relates to the underlying disease state. Some complications of CG predict poorer outcomes, however, including renal failure and development of a lymphoproliferative or plasma cell disorder. (See",
"      <a class=\"local\" href=\"#H43\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/1\">",
"      Ramos-Casals M, Stone JH, Cid MC, Bosch X. The cryoglobulinaemias. Lancet 2012; 379:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/2\">",
"      Wintrobe MM, Buell MV. Hyperproteinemia associated with multiple myeloma: with report of a case in which an extraordinary hyperproteinemia was associated with thrombosis of the retinal veins and symptoms suggesting Raynaud's disease. Bulletin of the Johns Hopkins Hospital 1933; 52:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/3\">",
"      LERNER AB, WATSON CJ. Studies of cryoglobulins; unusual purpura associated with the presence of a high concentration of cryoglobulin (cold precipitable serum globulin). Am J Med Sci 1947; 214:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/4\">",
"      Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/5\">",
"      Dispenzieri A, Gorevic PD. Cryoglobulinemia. Hematol Oncol Clin North Am 1999; 13:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/6\">",
"      Lamprecht P, Gause A, Gross WL. Cryoglobulinemic vasculitis. Arthritis Rheum 1999; 42:2507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/7\">",
"      Meltzer M, Franklin EC. Cryoglobulinemia--a study of twenty-nine patients. I. IgG and IgM cryoglobulins and factors affecting cryoprecipitability. Am J Med 1966; 40:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/8\">",
"      Meltzer M, Franklin EC, Elias K, et al. Cryoglobulinemia--a clinical and laboratory study. II. Cryoglobulins with rheumatoid factor activity. Am J Med 1966; 40:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/9\">",
"      Bonnet F, Pineau JJ, Taupin JL, et al. Prevalence of cryoglobulinemia and serological markers of autoimmunity in human immunodeficiency virus infected individuals: a cross-sectional study of 97 patients. J Rheumatol 2003; 30:2005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/10\">",
"      Garc&iacute;a-Carrasco M, Ramos-Casals M, Cervera R, et al. Cryoglobulinemia in systemic lupus erythematosus: prevalence and clinical characteristics in a series of 122 patients. Semin Arthritis Rheum 2001; 30:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/11\">",
"      Ramos-Casals M, Cervera R, Yag&uuml;e J, et al. Cryoglobulinemia in primary Sj&ouml;gren's syndrome: prevalence and clinical characteristics in a series of 115 patients. Semin Arthritis Rheum 1998; 28:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/12\">",
"      Cicardi M, Cesana B, Del Ninno E, et al. Prevalence and risk factors for the presence of serum cryoglobulins in patients with chronic hepatitis C. J Viral Hepat 2000; 7:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/13\">",
"      Ramos-Casals M, Mu&ntilde;oz S, Medina F, et al. Systemic autoimmune diseases in patients with hepatitis C virus infection: characterization of 1020 cases (The HISPAMEC Registry). J Rheumatol 2009; 36:1442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/14\">",
"      De Vita S, Soldano F, Isola M, et al. Preliminary classification criteria for the cryoglobulinaemic vasculitis. Ann Rheum Dis 2011; 70:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/15\">",
"      Brouet JC, Clauvel JP, Danon F, et al. Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med 1974; 57:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/16\">",
"      Musset L, Diemert MC, Taibi F, et al. Characterization of cryoglobulins by immunoblotting. Clin Chem 1992; 38:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/17\">",
"      Tissot JD, Schifferli JA, Hochstrasser DF, et al. Two-dimensional polyacrylamide gel electrophoresis analysis of cryoglobulins and identification of an IgM-associated peptide. J Immunol Methods 1994; 173:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/18\">",
"      Pascual M, Perrin L, Giostra E, Schifferli JA. Hepatitis C virus in patients with cryoglobulinemia type II. J Infect Dis 1990; 162:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/19\">",
"      Musset L, Duarte F, Gaillard O, et al. Immunochemical characterization of monoclonal IgG containing mixed cryoglobulins. Clin Immunol Immunopathol 1994; 70:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/20\">",
"      Kyle RA, Rajkumar SV. Monoclonal gammopathies of undetermined significance. Hematol Oncol Clin North Am 1999; 13:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/21\">",
"      Monti G, Galli M, Invernizzi F, et al. Cryoglobulinaemias: a multi-centre study of the early clinical and laboratory manifestations of primary and secondary disease. GISC. Italian Group for the Study of Cryoglobulinaemias. QJM 1995; 88:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/22\">",
"      Montagnino G. Reappraisal of the clinical expression of mixed cryoglobulinemia. Springer Semin Immunopathol 1988; 10:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/23\">",
"      Ramos-Casals M, Trejo O, Garc&iacute;a-Carrasco M, et al. Mixed cryoglobulinemia: new concepts. Lupus 2000; 9:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/24\">",
"      Antonelli A, Ferri C, Ferrari SM, et al. Serum levels of proinflammatory cytokines interleukin-1beta, interleukin-6, and tumor necrosis factor alpha in mixed cryoglobulinemia. Arthritis Rheum 2009; 60:3841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/25\">",
"      Fabris P, Tositti G, Giordani MT, et al. Prevalence and clinical significance of circulating cryoglobulins in HIV-positive patients with and without co-infection with hepatitis C virus. J Med Virol 2003; 69:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/26\">",
"      Belizna CC, Hamidou MA, Levesque H, et al. Infection and vasculitis. Rheumatology (Oxford) 2009; 48:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/27\">",
"      Ng YC, Schifferli JA. Clearance of cryoglobulins in man. Springer Semin Immunopathol 1988; 10:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/28\">",
"      Fornasieri A, Li M, Armelloni S, et al. Glomerulonephritis induced by human IgMK-IgG cryoglobulins in mice. Lab Invest 1993; 69:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/29\">",
"      Grey HM, Kohler PF. Cryoimmunoglobulins. Semin Hematol 1973; 10:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/30\">",
"      Ferraccioli GF, De Vita S, Casatta L, et al. Autoimmune connective tissue disease, chronic polyarthritides and B cell expansion: risks and perspectives with immunosuppressive drugs. Clin Exp Rheumatol 1996; 14 Suppl 14:S71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/31\">",
"      De Re V, De Vita S, Sansonno D, et al. Type II mixed cryoglobulinaemia as an oligo rather than a mono B-cell disorder: evidence from GeneScan and MALDI-TOF analyses. Rheumatology (Oxford) 2006; 45:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/32\">",
"      Pileri P, Uematsu Y, Campagnoli S, et al. Binding of hepatitis C virus to CD81. Science 1998; 282:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/33\">",
"      Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992; 327:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/34\">",
"      Agnello V. The etiology and pathophysiology of mixed cryoglobulinemia secondary to hepatitis C virus infection. Springer Semin Immunopathol 1997; 19:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/35\">",
"      Charles ED, Green RM, Marukian S, et al. Clonal expansion of immunoglobulin M+CD27+ B cells in HCV-associated mixed cryoglobulinemia. Blood 2008; 111:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/36\">",
"      Knight GB, Gao L, Gragnani L, et al. Detection of WA B cells in hepatitis C virus infection: a potential prognostic marker for cryoglobulinemic vasculitis and B cell malignancies. Arthritis Rheum 2010; 62:2152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/37\">",
"      Charles ED, Brunetti C, Marukian S, et al. Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset. Blood 2011; 117:5425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/38\">",
"      Schott P, Polzien F, M&uuml;ller-Issberner A, et al. In vitro reactivity of cryoglobulin IgM and IgG in hepatitis C virus-associated mixed cryoglobulinemia. J Hepatol 1998; 28:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/39\">",
"      Boyer O, Saadoun D, Abriol J, et al. CD4+CD25+ regulatory T-cell deficiency in patients with hepatitis C-mixed cryoglobulinemia vasculitis. Blood 2004; 103:3428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/40\">",
"      Kunkel HG, Winchester RJ, Joslin FG, Capra JD. Similarities in the light chains of anti-gamma-globulins showing cross-idiotypic specificities. J Exp Med 1974; 139:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/41\">",
"      Zinneman HH. Cryoglobulins and pyroglobulins. Pathobiol Annu 1980; 10:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/42\">",
"      Saha A, Chowdhury P, Sambury S, et al. Studies on cryoprecipitation. IV. Enzymic fragments of a human cryoglobulin. J Biol Chem 1970; 245:2730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/43\">",
"      Haakenstad AO, Mannik M. Saturation of the reticuloendothelial system with soluble immune complexes. J Immunol 1974; 112:1939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/44\">",
"      Hamburger MI, Gorevic PD, Lawley TJ, et al. Mixed cryoglobulinemia: association of glomerulonephritis with defective reticuloendothelial system Fc receptor function. Trans Assoc Am Physicians 1979; 92:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/45\">",
"      Berliner S, Weinberger A, Zamir R, et al. Familial cryoglobulinemia and C4 deficiency. Scand J Rheumatol 1984; 13:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/46\">",
"      McLean RH, Weinstein A, Chapitis J, et al. Familial partial deficiency of the third component of complement (C3) and the hypocomplementemic cutaneous vasculitis syndrome. Am J Med 1980; 68:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/47\">",
"      Trejo O, Ramos-Casals M, Garc&iacute;a-Carrasco M, et al. Cryoglobulinemia: study of etiologic factors and clinical and immunologic features in 443 patients from a single center. Medicine (Baltimore) 2001; 80:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/48\">",
"      Della Rossa A, Trevisani G, Bombardieri S. Cryoglobulins and cryoglobulinemia. Diagnostic and therapeutic considerations. Clin Rev Allergy Immunol 1998; 16:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/49\">",
"      Geltner D. Therapeutic approaches in mixed cryoglobulinemia. Springer Semin Immunopathol 1988; 10:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/50\">",
"      Gorevic PD, Kassab HJ, Levo Y, et al. Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients. Am J Med 1980; 69:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/51\">",
"      Cohen SJ, Pittelkow MR, Su WP. Cutaneous manifestations of cryoglobulinemia: clinical and histopathologic study of seventy-two patients. J Am Acad Dermatol 1991; 25:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/52\">",
"      Rossi D, Mansouri M, Baldovino S, et al. Nail fold videocapillaroscopy in mixed cryoglobulinaemia. Nephrol Dial Transplant 2004; 19:2245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/53\">",
"      Weinberger A, Berliner S, Pinkhas J. Articular manifestations of essential cryoglobulinemia. Semin Arthritis Rheum 1981; 10:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/54\">",
"      Ferri C, La Civita L, Cirafisi C, et al. Peripheral neuropathy in mixed cryoglobulinemia: clinical and electrophysiologic investigations. J Rheumatol 1992; 19:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/55\">",
"      Gemignani F, Pavesi G, Fiocchi A, et al. Peripheral neuropathy in essential mixed cryoglobulinaemia. J Neurol Neurosurg Psychiatry 1992; 55:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/56\">",
"      Garcia-Bragado F, Fernandez JM, Navarro C, et al. Peripheral neuropathy in essential mixed cryoglobulinemia. Arch Neurol 1988; 45:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/57\">",
"      Stricker RB, Sanders KA, Owen WF, et al. Mononeuritis multiplex associated with cryoglobulinemia in HIV infection. Neurology 1992; 42:2103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/58\">",
"      Stricker RB, Kiprov DD. Mononeuritis and cryoglobulins. Neurology 1993; 43:2159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/59\">",
"      Bombardieri S, Paoletti P, Ferri C, et al. Lung involvement in essential mixed cryoglobulinemia. Am J Med 1979; 66:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/60\">",
"      Viegi G, Fornai E, Ferri C, et al. Lung function in essential mixed cryoglobulinemia: a short-term follow-up. Clin Rheumatol 1989; 8:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/61\">",
"      Bertorelli G, Pesci A, Manganelli P, et al. Subclinical pulmonary involvement in essential mixed cryoglobulinemia assessed by bronchoalveolar lavage. Chest 1991; 100:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/62\">",
"      Levo Y, Gorevic PD, Kassab HJ, et al. Association between hepatitis B virus and essential mixed cryoglobulinemia. N Engl J Med 1977; 296:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/63\">",
"      Schena FP. Survey of the Italian Registry of Renal Biopsies. Frequency of the renal diseases for 7 consecutive years. The Italian Group of Renal Immunopathology. Nephrol Dial Transplant 1997; 12:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/64\">",
"      Tarantino A, De Vecchi A, Montagnino G, et al. Renal disease in essential mixed cryoglobulinaemia. Long-term follow-up of 44 patients. Q J Med 1981; 50:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/65\">",
"      Nash JW, Ross P Jr, Neil Crowson A, et al. The histopathologic spectrum of cryofibrinogenemia in four anatomic sites. Skin, lung, muscle, and kidney. Am J Clin Pathol 2003; 119:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/66\">",
"      Cohen P, Nguyen QT, D&eacute;ny P, et al. Treatment of mixed cryoglobulinemia with recombinant interferon alpha and adjuvant therapies. A prospective study on 20 patients. Ann Med Interne (Paris) 1996; 147:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/67\">",
"      Chad D, Pariser K, Bradley WG, et al. The pathogenesis of cryoglobulinemic neuropathy. Neurology 1982; 32:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/68\">",
"      Nemni R, Corbo M, Fazio R, et al. Cryoglobulinaemic neuropathy. A clinical, morphological and immunocytochemical study of 8 cases. Brain 1988; 111 ( Pt 3):541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/69\">",
"      Tredici G, Petruccioli MG, Cavaletti G, et al. Sural nerve bioptic findings in essential cryoglobulinemic patients with and without peripheral neuropathy. Clin Neuropathol 1992; 11:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/70\">",
"      Bonetti B, Invernizzi F, Rizzuto N, et al. T-cell-mediated epineurial vasculitis and humoral-mediated microangiopathy in cryoglobulinemic neuropathy. J Neuroimmunol 1997; 73:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/71\">",
"      Cavaletti G, Petruccioli MG, Crespi V, et al. A clinico-pathological and follow up study of 10 cases of essential type II cryoglobulinaemic neuropathy. J Neurol Neurosurg Psychiatry 1990; 53:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/72\">",
"      Ben-Bassat M, Boner G, Rosenfeld J, et al. The clinicopathologic features of cryoglobulinemic nephropathy. Am J Clin Pathol 1983; 79:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/73\">",
"      Beddhu S, Bastacky S, Johnson JP. The clinical and morphologic spectrum of renal cryoglobulinemia. Medicine (Baltimore) 2002; 81:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/74\">",
"      Dammacco F, Sansonno D. Mixed cryoglobulinemia as a model of systemic vasculitis. Clin Rev Allergy Immunol 1997; 15:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/75\">",
"      Tarantino A, Campise M, Banfi G, et al. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int 1995; 47:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/76\">",
"      Karras A, No&euml;l LH, Droz D, et al. Renal involvement in monoclonal (type I) cryoglobulinemia: two cases associated with IgG3 kappa cryoglobulin. Am J Kidney Dis 2002; 40:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/77\">",
"      Su CF, Chen HH, Yeh JC, et al. Ultrastructural 'fingerprint' in cryoprecipitates and glomerular deposits: a clinicopathologic analysis of fingerprint deposits. Nephron 2002; 90:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/78\">",
"      Monteverde A, Ballar&egrave; M, Bertoncelli MC, et al. Lymphoproliferation in type II mixed cryoglobulinemia. Clin Exp Rheumatol 1995; 13 Suppl 13:S141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/79\">",
"      Zignego AL, Giannelli F, Marrocchi ME, et al. Frequency of bcl-2 rearrangement in patients with mixed cryoglobulinemia and HCV-positive liver diseases. Clin Exp Rheumatol 1997; 15:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/80\">",
"      Szymanski IO, Pullman JM, Underwood JM. Electron microscopic and immunochemical studies in a patient with hepatitis C virus infection and mixed cryoglobulinemia type II. Am J Clin Pathol 1994; 102:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/81\">",
"      Bremmelgaard A, Nyg&aring;rd J. Interference by cryoglobulins with white blood cell measurements on Coulter Counter. Scand J Clin Lab Invest 1991; 51:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/82\">",
"      Luzar MJ, Camisa C, Neff JC. Essential mixed cryoglobulinemia (type II) with pseudoleukocytosis. Arthritis Rheum 1984; 27:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/83\">",
"      Tarantino A, Anelli A, Costantino A, et al. Serum complement pattern in essential mixed cryoglobulinaemia. Clin Exp Immunol 1978; 32:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/84\">",
"      Hebert LA, Cosio FG, Neff JC. Diagnostic significance of hypocomplementemia. Kidney Int 1991; 39:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/85\">",
"      Ferri C, Mannini L, Bartoli V, et al. Blood viscosity and filtration abnormalities in mixed cryoglobulinemia patients. Clin Exp Rheumatol 1990; 8:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/86\">",
"      Wener MH, Hutchinson K, Morishima C, Gretch DR. Absence of antibodies to cyclic citrullinated peptide in sera of patients with hepatitis C virus infection and cryoglobulinemia. Arthritis Rheum 2004; 50:2305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/87\">",
"      Misiani R, Bellavita P, Fenili D, et al. Hepatitis C virus infection in patients with essential mixed cryoglobulinemia. Ann Intern Med 1992; 117:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/88\">",
"      Levo Y. Hepatitis B virus and essential mixed cryoglobulinemia. Ann Intern Med 1981; 94:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/89\">",
"      Popp JW Jr, Dienstag JL, Wands JR, Bloch KJ. Essential mixed cryoglobulinemia without evidence for hepatitis B virus infection. Ann Intern Med 1980; 92:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/90\">",
"      Vermeersch P, Gijbels K, Mari&euml;n G, et al. A critical appraisal of current practice in the detection, analysis, and reporting of cryoglobulins. Clin Chem 2008; 54:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/91\">",
"      Trendelenburg M, Schifferli JA. Cryoglobulins are not essential. Ann Rheum Dis 1998; 57:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/92\">",
"      Della Rossa A, Tavoni A, D'Ascanio A, et al. Mortality rate and outcome factors in mixed cryoglobulinaemia: the impact of hepatitis C virus. Scand J Rheumatol 2010; 39:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/93\">",
"      Kay J, McCluskey RT. Case records of the Massachusetts General Hospital. Case 31-2005. A 60-year-old man with skin lesions and renal insufficiency. N Engl J Med 2005; 353:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/94\">",
"      Kallemuchikkal U, Gorevic PD. Evaluation of cryoglobulins. Arch Pathol Lab Med 1999; 123:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/95\">",
"      Shihabi ZK. Cryoglobulins: an important but neglected clinical test. Ann Clin Lab Sci 2006; 36:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/96\">",
"      Vermeersch P, Gijbels K, Knockaert D, et al. Establishment of reference values for immunoglobulins in the cryoprecipitate. Clin Immunol 2008; 129:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/97\">",
"      Invernizzi F, Pietrogrande M, Sagramoso B. Classification of the cryoglobulinemic syndrome. Clin Exp Rheumatol 1995; 13 Suppl 13:S123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/98\">",
"      Invernizzi F, Pioltelli P, Cattaneo R, et al. A long-term follow-up study in essential cryoglobulinemia. Acta Haematol 1979; 61:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/99\">",
"      La Civita L, Zignego AL, Monti M, et al. Mixed cryoglobulinemia as a possible preneoplastic disorder. Arthritis Rheum 1995; 38:1859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/100\">",
"      Saadoun D, Sellam J, Ghillani-Dalbin P, et al. Increased risks of lymphoma and death among patients with non-hepatitis C virus-related mixed cryoglobulinemia. Arch Intern Med 2006; 166:2101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/101\">",
"      Alberico S, Mazza S, Grimaldi E, et al. Essential mixed type II cryoglobulinemia in a HCV positive pregnant woman: case report. Clin Exp Obstet Gynecol 1998; 25:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/102\">",
"      Sibilia J, Feugeas O, Laugel V, et al. Successful management of neonatal cryoglobulinaemia after a gemellar pregnancy in a woman with symptomatic type I cryoglobulinaemia. Ann Rheum Dis 2004; 63:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/63/22522/abstract/103\">",
"      Laugel V, Goetz J, Wolff S, et al. Neonatal management of symptomatic transplacental cryoglobulinaemia. Acta Paediatr 2004; 93:556.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1825 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-201.211.0.116-3897C101CA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_63_22522=[""].join("\n");
var outline_f21_63_22522=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5780053\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CRYOGLOBULIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CRYOGLOBULINEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Prevalence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Analysis of cryoglobulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Brouet classification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ETIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Type I CG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Types II and III CG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Aggregation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Type I CG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Mixed CGs (Types II and III)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Cutaneous",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Musculoskeletal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Neuropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Pulmonary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Renal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      PATHOLOGICAL FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Cutaneous",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Peripheral nerve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Renal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Light and immunofluorescence microscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Electron microscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Bone marrow",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      LABORATORY FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Cryoglobulins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Complement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Acute phase reactants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Autoantibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Evidence of viral infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Detection and analysis of cryoglobulins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Syndromic diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Differential diagnosis (DDX)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      - DDX: Cryoglobulinemic vasculitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      - DDX: Cryoglobulinemic hyperviscosity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Survival",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Renal failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      Lymphoproliferative disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5780053\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/1825\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/1825|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/11/33970\" title=\"picture 1\">",
"      Cryocrit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/0/19461\" title=\"picture 2\">",
"      Palpable purpura from vasculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/57/29593\" title=\"picture 3\">",
"      MPGN in mixed cryo Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/43/4793\" title=\"picture 4\">",
"      Skin lesion in mixed cryo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/26/40367\" title=\"picture 5\">",
"      IgM deposits in mixed cryo IF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/59/23481\" title=\"picture 6\">",
"      Subendothelial deposits in mixed cryo EM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/5/35929\" title=\"picture 7\">",
"      Fingerprint pattern in mixed cryo EM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/1825|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/11/37052\" title=\"table 1\">",
"      Classification of cryoglobulins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/47/14077\" title=\"table 2A\">",
"      Diseases assoc with cryos I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/48/3853\" title=\"table 2B\">",
"      Diseases assoc with cryos II",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=related_link\">",
"      Classification of and approach to the vasculitides in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=related_link\">",
"      Clinical features, laboratory manifestations, and diagnosis of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34040?source=related_link\">",
"      Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22423?source=related_link\">",
"      Clinical manifestations of vasculitic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7576?source=related_link\">",
"      Cryofibrinogenemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/47/762?source=related_link\">",
"      Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15498?source=related_link\">",
"      Extrahepatic manifestations of hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/12/12484?source=related_link\">",
"      Plasma exchange in the hyperviscosity syndrome due to immunoglobulins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/58/10154?source=related_link\">",
"      Recognition of monoclonal proteins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37353?source=related_link\">",
"      Renal disease associated with hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37626?source=related_link\">",
"      Treatment and prognosis of Waldenstr&ouml;m macroglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/52/36682?source=related_link\">",
"      Treatment of the mixed cryoglobulinemia syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_63_22523="Reconstruction techniques for contractures from burns";
var content_f21_63_22523=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F73863&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F73863&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Reconstruction techniques for contractures from burns",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Type of burn contracture",
"       </td>",
"       <td class=\"subtitle1\">",
"        Condition of adjacent skin and tissue",
"       </td>",
"       <td class=\"subtitle1\">",
"        Reconstruction technique options",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isolated linear",
"       </td>",
"       <td>",
"        Healthy, unburned, or elastic skin and tissue at both sides of the contracture",
"       </td>",
"       <td>",
"        <p>",
"         Z-plasty - if realignment via transposition with moderate elongation needs to be achieved",
"        </p>",
"        <p>",
"         Y-V-plasty - if realignment via advancement of transposing flaps needs to be achieved with introduction of pliable tissue",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isolated linear",
"       </td>",
"       <td>",
"        Healthy, unburned, or elastic skin and tissue at only one side of the contracture",
"       </td>",
"       <td>",
"        Local fasciocutaneous transposition flap",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multiple linear",
"       </td>",
"       <td>",
"        Wide contractures or no healthy adjacent skin or tissue on either side of contracture",
"       </td>",
"       <td>",
"        <p>",
"         Dermal skin substitute with split thickness skin graft",
"        </p>",
"        <p>",
"         Regional, distant, or free flap",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_63_22523=[""].join("\n");
var outline_f21_63_22523=null;
var title_f21_63_22524="Noninfectious causes fever";
var content_f21_63_22524=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F68779&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F68779&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Noninfectious causes of fever in the intensive care unit",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Important causes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Acalculous cholecystitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Adrenal insufficiency",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Benign post-operative fever",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Drug fever",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pancreatitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Thyroid storm",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Transfusion reaction",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Other causes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Acute respiratory distress syndrome (late)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Burns",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Drug overdose (eg, aspirin anticholinergic drugs)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Drug withdrawal",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Gout",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Heat stroke",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Intracranial hemorrhage",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ischemic colitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Malignancy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Malignant hyperthermia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Myocardial infarction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Neuroleptic malignant syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pheochromocytoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Seizures",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Serotonin syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Thromboembolic disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Vasculitis",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_63_22524=[""].join("\n");
var outline_f21_63_22524=null;
var title_f21_63_22525="CL treatment";
var content_f21_63_22525=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F88693&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F88693&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drug regimens for treatment of cutaneous leishmaniasis in adults",
"    <sup>",
"     [1-3]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"20%\">",
"     </colgroup>",
"     <colgroup span=\"2\" width=\"40%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Local therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Pentavalent antimonials",
"       </td>",
"       <td>",
"        Sodium stibogluconate*",
"       </td>",
"       <td>",
"        0.5 to 2 mL intralesionally every three to seven days until healed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meglumine antimoniate",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.5 to 2 mL intralesionally every three to seven days until healed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Paromomycin",
"       </td>",
"       <td>",
"        Paromomycin ointment",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        Apply topically to lesions twice daily for 10 to 20 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        WR 279396 cream",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        Apply topically to lesions once daily for 20 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Oral systemic therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Azoles",
"       </td>",
"       <td>",
"        Fluconazole",
"       </td>",
"       <td>",
"        200 to 600 mg orally once daily for six weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ketoconazole",
"       </td>",
"       <td>",
"        600 mg orally once daily for 28 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Itraconazole",
"       </td>",
"       <td>",
"        100 to 200 mg orally twice daily for 28 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Miltefosine",
"       </td>",
"       <td>",
"        Miltefosine",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        2.5 mg/kg (maximum 150 mg) orally once daily for 28 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Parenteral systemic therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Pentavalent antimonials",
"       </td>",
"       <td>",
"        Sodium stibogluconate",
"       </td>",
"       <td>",
"        20 mg/kg/day intravenously or intramuscularly for 10 to 20 days",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meglumine antimoniate",
"       </td>",
"       <td>",
"        20 mg/kg/day intravenously or intramuscularly for 10 to 20 days",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Amphotericin",
"       </td>",
"       <td>",
"        Amphotericin B deoxycholate",
"       </td>",
"       <td>",
"        0.5 to 1 mg/kg intravenously every other day for 20 to 30 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Liposomal amphotericin B (AmBisome)",
"       </td>",
"       <td>",
"        3 mg/kg intravenously daily for five to seven doses; if immunocompromised host then give 4 mg/kg for ten or more doses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pentamidine",
"       </td>",
"       <td>",
"        Pentamidine isethionate",
"       </td>",
"       <td>",
"        2 to 4 mg/kg intravenously or intramuscularly every other day for four to seven doses or until healed",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Agents listed, dosage regimens, and combinations are effective only against certain Leishmania species/strains and only in certain areas of the world. The therapeutic approach to cutaneous leishmaniasis is discussed in the topic 'Treatment of cutaneous leishmaniasis.' Pediatric dosing is summarized separately",
"    <sup>",
"     [3]",
"    </sup>",
"    .",
"    <div class=\"footnotes\">",
"     * In the United States, may be obtained from CDC Drug Services telephone 404-639-3670 or 404-639-2888 (nights, weekends).",
"     <br>",
"      &Delta; Not commercially available in US. It may be possible to obtain via investigational new drug application.",
"      <br>",
"       <font class=\"lozenge\">",
"        &loz;",
"       </font>",
"       Compounding instructions and additional information is summarized separately",
"       <sup>",
"        [3]",
"       </sup>",
"       .",
"       <br>",
"        &sect; For treatment of CL among military healthcare beneficiaries in the United States, may be obtained from US Army Medical Materiel Development Activity.",
"        <br>",
"         &yen; Duration of 10 days is appropriate for treatment of relatively mild disease with evidence of clinical response by day 10; otherwise, the duration should be extended. Duration of 20 days is appropriate for treatment of CL due to species known to cause mucosal disease.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of authors with additional data from:",
"     <br/>",
"     <ol>",
"      <li>",
"       Goto H and Laulett Lindoso JA; Cutaneous and mucocutaneous leishmaniasis; Inf Dis Clin N Am 2012; 26:293.",
"      </li>",
"      <li>",
"       Parasites - Leishmaniasis; Centers for Disease Control and Prevention",
"       <a href=\"file://www.cdc.gov/parasites/leishmaniasis/health_professionals/index.html#tx\" target=\"_blank\">",
"        file://www.cdc.gov/parasites/leishmaniasis/health_professionals/index.html#tx",
"       </a>",
"       (accessed March 25, 2013).",
"      </li>",
"      <li>",
"       Drugs for parasitic infections 2nd ed; The Medical Letter 2010; New Rochelle N.Y. p.26.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_63_22525=[""].join("\n");
var outline_f21_63_22525=null;
var title_f21_63_22526="DDx vomiting children";
var content_f21_63_22526=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79114&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79114&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of vomiting in infants and children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Gastrointestinal disorders",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Obstruction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Esophageal, pyloric, or intestinal stenosis, atresia, or web",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Foreign body",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Esophageal, gastric, or intestinal duplication",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Gastric bezoar, volvulus, or tumor",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Intestinal malrotation or volvulus*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Intermittent intussusception",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Duodenal or intestinal hematoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Superior mesenteric artery syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Intestinal pseudo-obstruction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Adhesions, including congenital adhesions",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Incarcerated hernia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Tumors",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Meconium ileus or equivalent",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hirschsprung disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Imperforate anus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Other GI disorders",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Gastroesophageal reflux",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Chalasia or achalasia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Tracheoesophageal fistula",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Peptic ulcer",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Gastritis, esophagitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Eosinophilic esophagitis/gastroenteritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Gastroparesis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Appendicitis*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Ulcerative colitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Pancreatitis*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Cholecystitis, cholelithiasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Choledochal cyst",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Food intolerance or allergy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Genitourinary causes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hydronephrosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Urinary tract obstruction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pregnancy*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Renal stones",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hydrometrocolpos",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Testicular or ovarian torsion",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Renal insufficiency",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Toxic ingestions",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lead intoxication",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Iron intoxication",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Vitamin A or D intoxication",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Organophosphate exposure",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Medications (ipecac, digoxin, theophylline)",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Infectious causes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Gastroenteritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sepsis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Meningitis, encephalitis, or brain abscess*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pneumonia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pyelonephritis*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hepatitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hepatic abscess",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Group A streptococcal infections",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Endocrine and metabolic causes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Diabetic ketoacidosis*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Amino acid and organic acid disorders*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fatty acid oxidation defects",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Uremia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypercalcemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Renal tubular acidosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Congenital adrenal hyperplasia*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Diabetes insipidus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Galactosemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fructose intolerance",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Urea cycle defects",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Maple syrup urine disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Glycogen storage disease, type 1",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Neurologic causes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Migraine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Trauma*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Brain tumor*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hydrocephalus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Increased intracranial pressure*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Epilepsy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Subdural hematoma*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Intracranial hemorrhage*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Miscellaneous causes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Poor feeding technique",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Improper formula preparation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Excessive air swallowing",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Inappropriate handling after feeding",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Psychogenic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Coughing",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Postnasal drip",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cyclic vomiting",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cricopharyngeal incoordination",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Vestibular injury or inflammation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Heart failure",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Important causes to remember.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Vomiting. In: Signs and Symptoms in Pediatrics, 3rd ed, Tunnessen, WW Jr, Roberts, KB (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia, 1999. p. 491 and Pediatrics GE reflux clinical practice guidelines. J Pediatr Gastroenterol and Nutr 2001; 32:S1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_63_22526=[""].join("\n");
var outline_f21_63_22526=null;
var title_f21_63_22527="Cervical wedge fracture close up";
var content_f21_63_22527=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F55806&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F55806&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cervical anterior wedge fracture: Lateral view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 507px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Anterior wedge fractures result from extreme flexion. Spinal instability can occur with severe anterior wedge fractures (loss of over half the vertebral height) or multiple adjacent wedge fractures.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mary Hochman, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_63_22527=[""].join("\n");
var outline_f21_63_22527=null;
